var title_f31_34_32288="Ultrasound appearance of a breast abscess";
var content_f31_34_32288=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound appearance of a breast abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 307px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This image shows an abscess in the breast using ultrasound.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Dixon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_34_32288=[""].join("\n");
var outline_f31_34_32288=null;
var title_f31_34_32289="Milex incontinence ring pessary";
var content_f31_34_32289=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Milex incontinence vaginal ring",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 417px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ball portion of the pessary lies below the urethrovesical junction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Milex Products, Inc., Chicago, IL.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_34_32289=[""].join("\n");
var outline_f31_34_32289=null;
var title_f31_34_32290="Patient information: Taking medicines when you're older (The Basics)";
var content_f31_34_32290=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/30/483\">",
"         Patient information: Dealing with side effects from medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/16/34050\">",
"         Patient information: Going home from the hospital (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?36/43/37554\">",
"         Patient information: Medicine brand and generic names (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/6/11363\">",
"         Patient information: Narcotic pain medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?26/36/27202\">",
"         Patient information: When you have multiple health problems (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/61/32726\">",
"         Patient information: Reducing the costs of medicines (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Taking medicines when you're older (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/taking-medicines-when-youre-older-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H4946088\">",
"      <span class=\"h1\">",
"       Are some medicines unsafe for older people?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, some medicines that are safe for younger adults are not safe for older adults. That&rsquo;s because as people get older, unwanted or harmful side effects from certain medicines become more common. Plus, the medicines last longer in the body.",
"     </p>",
"     <p>",
"      The next time you see your doctor or nurse, put all the medicines you take into a bag and bring them with you. Make sure you include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        All your prescription medicines",
"       </li>",
"       <li>",
"        All the non-prescription medicines you take, including vitamins and medicines such as Tylenol&reg; or Advil&reg;",
"       </li>",
"       <li>",
"        Any herbal or &ldquo;natural&rdquo; products you take",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      During your visit:",
"      <br/>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Ask if you should still be taking all of the medicines you currently take. People sometimes end up taking more medicines than they really need. &nbsp;",
"       </li>",
"       <li>",
"        Ask whether the combination of medicines you take could cause a problem or &ldquo;drug interaction.&rdquo; A drug interaction is when a medicine, food, or supplement changes the effects of another medicine. &nbsp;",
"       </li>",
"       <li>",
"        Tell your doctor or nurse about any symptoms you are having that you think are due to one of your medicines. He or she might be able to lower your dose, switch you to a different medicine, or deal with the symptoms in other ways.",
"       </li>",
"       <li>",
"        Tell your doctor or nurse if you can&rsquo;t afford your medicines. He or she might be able to switch you to a less expensive medicine or suggest other solutions.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4946103\">",
"      <span class=\"h1\">",
"       Interactions",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sometimes 2 medicines that are safe to take by themselves are actually unsafe to take together. When certain medicines are taken together, they can cause serious side effects or other problems. This can happen not just when 2 medicines are combined, but also when a medicine is combined with a specific food, or an herbal drug. Here are some examples:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/2/33830?source=see_link\">",
"         Warfarin",
"        </a>",
"        <strong>",
"         (brand name: Coumadin&reg;) +",
"        </strong>",
"        <strong>",
"         ginkgo biloba",
"        </strong>",
"        <strong>",
"        </strong>",
"        &ndash; The prescription medicine warfarin helps keeps blood clots from forming. People take it to prevent strokes, heart attacks, and other problems. Ginkgo biloba is an herbal drug that is popular in the US. People take it for lots of reasons, including the hope that it will keep them mentally sharp. But when the 2 drugs are taken together, they can seriously increase the risk of bleeding.",
"       </li>",
"       <li>",
"        <strong>",
"         Saint John&rsquo;s wort + antidepressants",
"        </strong>",
"        &ndash; The herbal drug Saint John's wort can help with mild forms of depression. But people sometimes take it when they're already taking an antidepressant. This combination can have dangerous consequences. It can lead to a condition called serotonin syndrome, which is life-threatening.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4946118\">",
"      <span class=\"h1\">",
"       Side effects",
"      </span>",
"      &nbsp;&mdash;&nbsp;People of all ages can have side effects from medicines, but older people are more likely to have some side effects. For example, older people are more likely to feel sleepy, confused, dizzy, or unsteady with certain medicines. This can be especially dangerous for them, because it increases the chances that they will fall.",
"     </p>",
"     <p>",
"      If you tend to feel sleepy, confused, dizzy, or unsteady, tell your doctor or nurse. Your medicines may or may not be the reason for your symptoms. Either way, it's important for your doctor or nurse to know about them. And if the symptoms are side effects of your medicines, your doctor or nurse might be able to lower your dose, switch you to a different medicine, or offer another solution.",
"     </p>",
"     <p>",
"      A common side effect in older men is trouble urinating. A number of different medicines can cause this side effect, including allergy medicines or sleeping pills. Talk to your doctor if you start a new medicine and find you have trouble starting the flow of urine, or your urine stream is weaker than it used to be.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4946135\">",
"      <span class=\"h1\">",
"       Ways to protect yourself",
"      </span>",
"      &nbsp;&mdash;&nbsp;To lower the chances that you'll have problems related to the medicines you take, follow these steps:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Make sure that your main doctor, and any other doctor or nurse who prescribes medicines for you knows about",
"        <strong>",
"         all",
"        </strong>",
"        of the medicines you take. This includes any over-the-counter or herbal medicines you use on a regular basis. Ask your doctor or nurse to go over all your medicines with you at least once a year.",
"       </li>",
"       <li>",
"        Keep a list of all the medicines you take that includes the dose you take, your reason for taking it, and the doctor or nurse who prescribed it. You can find an example of this kind of list at the following web site:",
"        <a class=\"external\" href=\"file://www.fda.gov/drugs/resourcesforyou/ucm079489.htm\">",
"         www.fda.gov/Drugs/ResourcesForYou/ucm079489.htm",
"        </a>",
"        .",
"       </li>",
"       <li>",
"        Anytime your doctor or nurse puts you on a new medicine, ask:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Why am I taking this medicine?",
"       </li>",
"       <li>",
"        What are the common problems to watch out for?",
"       </li>",
"       <li>",
"        What should I do if they happen?",
"       </li>",
"       <li>",
"        When should I stop this medicine?",
"       </li>",
"       <li>",
"        Can I take this medicine with the other medicines on my list?",
"       </li>",
"       <li>",
"        What will happen if I don't take this medicine?",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        When you pick up a new prescription, ask your pharmacist if there are foods, supplements, or other medicines that you should avoid while taking your medicine. Your pharmacist is a great resource. Ask him or her any questions you might have about your medicines.",
"       </li>",
"       <li>",
"        Keep medicines in their original containers and read the instructions that come with them.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H4946152\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/43/37554?source=see_link\">",
"       Patient information: Medicine brand and generic names (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/16/34050?source=see_link\">",
"       Patient information: Going home from the hospital (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/30/483?source=see_link\">",
"       Patient information: Dealing with side effects from medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/6/11363?source=see_link\">",
"       Patient information: Narcotic pain medicines (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/36/27202?source=see_link\">",
"       Patient information: When you have multiple health problems (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=see_link\">",
"       Patient information: Reducing the costs of medicines (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/34/32290?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16625 Version 6.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-071942397F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_34_32290=[""].join("\n");
var outline_f31_34_32290=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4946088\">",
"      Are some medicines unsafe for older people?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4946103\">",
"      Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4946118\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4946135\">",
"      Ways to protect yourself",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4946152\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/30/483?source=related_link\">",
"      Patient information: Dealing with side effects from medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/16/34050?source=related_link\">",
"      Patient information: Going home from the hospital (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/43/37554?source=related_link\">",
"      Patient information: Medicine brand and generic names (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/6/11363?source=related_link\">",
"      Patient information: Narcotic pain medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/36/27202?source=related_link\">",
"      Patient information: When you have multiple health problems (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_34_32291="Regadenoson: Patient drug information";
var content_f31_34_32291=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Regadenoson: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/38/23140?source=see_link\">",
"     see \"Regadenoson: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6139005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lexiscan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691293",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used during a stress test of the heart.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to regadenoson or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a slow heartbeat without a working pacemaker.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696751",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat or drink anything that has caffeine (for example, tea, coffee, cola, and chocolate) for 12 hours before using this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3532549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing. Slow breathing, shallow breathing, or trouble breathing are all signs of this. Call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698147",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High or low blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698654",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12104 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-AB43D6AFE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_34_32291=[""].join("\n");
var outline_f31_34_32291=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6139005\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029587\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029586\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029590\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029591\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029593\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029589\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029594\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029595\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?22/38/23140?source=related_link\">",
"      Regadenoson: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_34_32292="Laparoscopy LUQ entry";
var content_f31_34_32292=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Left upper quadrant laparoscopy entry sites",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 567px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_34_32292=[""].join("\n");
var outline_f31_34_32292=null;
var title_f31_34_32293="Nutrition label sodium PI";
var content_f31_34_32293=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F56605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F56605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    Reading sodium content from the nutrition label",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 446px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    When calculating sodium content, be sure to note the serving size (1 cup in this example).",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_34_32293=[""].join("\n");
var outline_f31_34_32293=null;
var title_f31_34_32294="Principles of component separation technique for complex abdominal wall defects and hernias";
var content_f31_34_32294=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Principles of component separation technique for complex abdominal wall defects and hernias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/34/32294/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/34/32294/contributors\">",
"     John Cone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/34/32294/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/34/32294/contributors\">",
"     Richard Turnage, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/34/32294/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/34/32294/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/34/32294/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H26505312\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Component Separation Technique (CST), a type of rectus abdominis muscle advancement flap, was first used to reconstitute the linea alba, reduce abdominal wall tension, and provide a dynamic abdominal wall in patients with large abdominal wall defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/1\">",
"     1",
"    </a>",
"    ]. CST allows reconstruction of a large defect without requiring a free distant transposition flap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/2\">",
"     2",
"    </a>",
"    ]. Despite the relatively high frequency of recurrent abdominal wall incisional hernias, there is no consensus on the optimal repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The advantages of CST are that it restores structural support of the abdominal wall, provides stable soft tissue coverage, and optimizes esthetic appearance of complex abdominal wall defects and giant midline abdominal wall hernias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of CST to reconstruct large and complex abdominal wall defects is discussed here. An overview of abdominal wall defects and reconstruction of sternal defects and mastectomy defects with rectus abdominis muscle flaps are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/49/43801?source=see_link\">",
"     \"Overview of abdominal hernias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14858?source=see_link\">",
"     \"Surgical management of sternal wound complications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39386?source=see_link\">",
"     \"Breast reconstruction in women with breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25488179\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complex abdominal wall defects, including incisional abdominal wall hernias, are a challenging surgical problem. Incisional hernias occur in 10 to 23 percent of open abdominal laparotomies, with recurrence rates reported between 18 and 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/49/43801?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of abdominal hernias\", section on 'Outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite this relatively high frequency of recurrent incisional hernias, there is no consensus on the optimal repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. A large number of surgical repairs have been described, including primary suture repair and prosthetic material (mesh) repair, but neither is ideal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/9\">",
"     9",
"    </a>",
"    ]. Primary repair is associated with a high recurrence rate and mesh repairs are associated with a higher infection rate than repairs without mesh. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/14/43239?source=see_link\">",
"     \"Wound infections following abdominal wall hernia repair: Epidemiology, pathogenesis, and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other disadvantages of synthetic or biologic prosthetic materials include a lack of support for dynamic abdominal wall function, recurrence rates of 10 to 20 percent, and in cases where there is little soft tissue coverage, a high risk of prosthetic extrusion and an increased risk of infected mesh and enterocutaneous fistulae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal repair of an incisional hernia or abdominal wall defect includes the following goals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prevent visceral eventration",
"     </li>",
"     <li>",
"      Incorporate the abdominal wall",
"     </li>",
"     <li>",
"      Provide a tension free repair",
"     </li>",
"     <li>",
"      Provide dynamic muscle support",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The CST, a method to repair large and complex abdominal wall defects, was developed as an alternative to the use of prosthetic material [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/1\">",
"     1",
"    </a>",
"    ]. It is based on the principle of enlarging the circumference of the abdominal wall surface by moving muscle layers to bridge a fascial defect as large as 20 cm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/13\">",
"     13",
"    </a>",
"    ]. The advantages of the CST, a type of rectus abdominis muscle advancement flap, is that it provides for a tension free repair, has sufficient bulk to prevent visceral eventration, and is well vascularized. The flap can be advanced with or without the overlying skin.",
"   </p>",
"   <p>",
"    The success of the CST is attributed to the following five principles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/3,14\">",
"     3,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Translation of the muscular layer of the abdominal wall to enlarge the tissue surface area",
"     </li>",
"     <li>",
"      Separation of muscle layers to allow maximal individual expansion of each muscle unit",
"     </li>",
"     <li>",
"      Disconnection of the muscle unit from its fascial sheath envelope to facilitate expansion",
"     </li>",
"     <li>",
"      Use of abdominal wall musculature to cover intraabdominal contents",
"     </li>",
"     <li>",
"      Use of bilateral mobilization rather than unilateral advancement for equilibrating forces of the abdominal wall and centralizing the midline",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25488188\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;This technique is the preferred approach by the authors for reapproximating the midline for all ventral hernias, except for very small defects or in those cases in which reapproximation is not feasible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/1\">",
"     1",
"    </a>",
"    ]. Its greatest utility is in repairing large midline defects less than 20 cm in diameter. Indications for CST include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repair of large abdominal wall incisional hernias that cannot be closed primarily",
"     </li>",
"     <li>",
"      Repair of recurrent, large abdominal wall incisional hernias that have failed primary closure or prosthetic repairs",
"     </li>",
"     <li>",
"      Reconstruction of abdominal wall defects resulting from trauma, infection, or malignancy",
"     </li>",
"     <li>",
"      Reconstruction of giant omphaloceles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25488672\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications for a rectus abdominis muscle advancement flap include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compromised vascular supply (eg, superior epigastric artery, deep inferior epigastric artery) to the rectus flap. However, this is a relative contraindication as the remaining blood supply to the rectus muscle is primarily through collaterals from the internal oblique and the transversus abdominis muscles and these vessels are preserved in CST.",
"     </li>",
"     <li>",
"      Extensive destruction of the components of the abdominal wall",
"     </li>",
"     <li>",
"      Reconstruction in a contaminated field",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25487965\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with midline abdominal wall defects are the optimal candidates for a repair by CST. CST may be a useful repair for large defects as it allows for a relatively small adynamic area of abdominal wall. In some patients with extremely large defects, even CST may not allow restoration of the abdominal wall without excessive tension. When a defect is too large to close primarily by CST, the options are an advancement flap with a prosthetic or biologic mesh to bridge the defect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26505326\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF THE SURGICAL TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preoperative clinical assessment is the key component to determining if a patient is a candidate for repair of a complex abdominal wall defect by a rectus advancement flap (",
"    <a class=\"graphic graphic_figure graphicRef73555 \" href=\"mobipreview.htm?34/1/34846\">",
"     figure 1",
"    </a>",
"    ). In addition, the intraoperative dissection must be meticulous to preserve blood supply and innervation of the flap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/5,16\">",
"     5,16",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25488798\">",
"    <span class=\"h2\">",
"     Preoperative assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful history and physical examination are critical to ascertain what components of the anterior abdominal wall remain undisturbed from prior surgical procedures, tumors, infection, trauma, or congenital defects (",
"    <a class=\"graphic graphic_figure graphicRef77053 \" href=\"mobipreview.htm?28/40/29320\">",
"     figure 2",
"    </a>",
"    ). If the clinical examination cannot identify an intact rectus abdominis muscle and fascia, CT scan, or magnetic resonance imaging can be useful for identifying remaining anatomic structures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25488810\">",
"    <span class=\"h2\">",
"     Intraoperative procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A brief description of the procedure is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first surgical step is to elevate the skin and subcutaneous tissues from the underlying fascia, extending from the costal margin cephalad to the pubis caudally, and to the anterior axillary line and iliac crest laterally (",
"      <a class=\"graphic graphic_figure graphicRef50539 \" href=\"mobipreview.htm?28/5/28752\">",
"       figure 3",
"      </a>",
"      ) .",
"     </li>",
"     <li>",
"      An incision is made in the external oblique aponeurosis 2 cm lateral to the semilunar line and extending from the costal margin to the inguinal ligament.",
"     </li>",
"     <li>",
"      The external oblique muscle is bluntly dissected from the underlying internal oblique muscle (",
"      <a class=\"graphic graphic_figure graphicRef76185 \" href=\"mobipreview.htm?33/33/34320\">",
"       figure 4",
"      </a>",
"      ). Meticulous care is taken not to disrupt the internal oblique muscle and to avoid disrupting the neurovascular supply. This should result in approximately 5 cm of advancement",
"      <strong>",
"      </strong>",
"      in the upper third of the abdomen, 10 cm in the mid-abdomen, and 3 cm in the lower third of the abdomen.",
"     </li>",
"     <li>",
"      If there is insufficient advancement of the musculofascial flap to the midline, the rectus muscle may be dissected free of its posterior sheath (",
"      <a class=\"graphic graphic_figure graphicRef55185 \" href=\"mobipreview.htm?11/57/12191\">",
"       figure 5",
"      </a>",
"      ). This secondary release should produce an additional 2 to 4 cm of flap advancement. Thus, in the middle third of the abdomen, a total of 20 cm of advancement is often possible (",
"      <a class=\"graphic graphic_figure graphicRef68977 \" href=\"mobipreview.htm?29/0/29710\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Drains are almost universally employed in an effort to prevent seromas that can occur beneath the skin flaps and adjacent to prosthetic material. There are no prospective trials regarding optimal placement of drains or timing of their removal. Even closed suction drains are associated with an increased risk of infection. Thus, many surgeons are reluctant to leave them in place for extended periods of time or to place them in direct contact with prosthetic material. The use of a drain is dependent on surgeon preference.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25488827\">",
"    <span class=\"h2\">",
"     Modifications of the technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modifications of the above procedure include use of endoscopic-assisted CST or mesh. Modification may be needed due to unexpected or adverse conditions identified during the procedure (eg, excessive tension). Modification of CST is required in cases where there is atrophy of the abdominal wall or the presence of an ostomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7144726\">",
"    <span class=\"h3\">",
"     Endoscopic assisted CST",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the major disadvantages of the traditional open CST is the necessity for creating both a large exposed surface area and relatively ischemic skin flaps, predisposing the patient to surgical site infection. An endoscopically assisted approach to component separation minimizes vascular damage since it avoids dividing the perforators arising from the epigastric vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/7\">",
"     7",
"    </a>",
"    ]. A review of seven patients treated with endoscopic assisted CST found fewer wound infections compared with 30 patients undergoing traditional open CST (0 versus 40 percent wound infections), fewer midline ischemic wounds (0 versus 20 percent), and fewer wound dehiscences (0 versus 43 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/7\">",
"     7",
"    </a>",
"    ]. A disadvantage of the endoscopic assisted CST is that the maximum flap advancement is reduced by 1 to 2 cm per side.",
"   </p>",
"   <p>",
"    The differences between the endoscopic and traditional open technique include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin and subcutaneous tissue flaps are elevated for only a 1 cm margin over the rectus sheath to avoid disruption of the perforating vessels from the anterior surface of the rectus muscle (",
"      <a class=\"graphic graphic_figure graphicRef76703 \" href=\"mobipreview.htm?5/5/5215\">",
"       figure 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A short incision is made 5 cm medial to the anterior superior iliac spine. Blunt dissection is performed to expose the fascia (",
"      <a class=\"graphic graphic_figure graphicRef69854 \" href=\"mobipreview.htm?30/20/31055\">",
"       figure 8",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A balloon dissector is utilized to develop a vertical subcutaneous pocket. This space is insufflated and two more ports are introduced just below the costal margin and 3 cm medial to the first trocar site (",
"      <a class=\"graphic graphic_figure graphicRef68208 \" href=\"mobipreview.htm?30/10/30895\">",
"       figure 9",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The external oblique aponeurosis is incised endoscopically in the same location that would be employed for an open component separation. The plane between the external and internal oblique muscles is developed bluntly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7144654\">",
"    <span class=\"h3\">",
"     Abdominal wall atrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the abdominal wall appears excessively thin at the site of the incision in the external oblique, particularly in patients whose abdominal wall is somewhat atrophic, the area should be reinforced with absorbable mesh to serve as a stimulus for additional fibrosis and to reduce the risk of herniation through this site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H262915984\">",
"    <span class=\"h3\">",
"     Ostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with an enterostomy, a modified components separation technique is used. The skin and subcutaneous tissue are not dissected from the rectus sheath. Instead, the external oblique aponeurosis is incised via two separate lateral incisions. The ostomy is advanced with the rectus flap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25488952\">",
"    <span class=\"h3\">",
"     Reinforcing materials",
"    </span>",
"    &nbsp;&mdash;&nbsp;If tension on the CST repair is too great, or if the abdominal wall is too weak, the reconstituted linea alba should be reinforced by a patch of either prosthetic or biologic material. If a patch is required for the repair, the next decision is whether to place it intraperitoneally in an underlay fashion or subcutaneously in an onlay fashion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/37/24151?source=see_link&amp;anchor=H10#H10\">",
"     \"Parastomal hernia\", section on 'Repair using prosthetic mesh'",
"    </a>",
"    .) Our preference is for the intraperitoneal underlay technique. This preference is based on higher incidence of surgical site infections in all open hernia repairs with mesh. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/14/43239?source=see_link\">",
"     \"Wound infections following abdominal wall hernia repair: Epidemiology, pathogenesis, and prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/0/11268?source=see_link\">",
"     \"Infection in mesh graft following hernia repair: Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a patch is utilized to reinforce the primary component separation repair, it should extend sufficiently far laterally to cover the site of the incision in the external oblique aponeurosis. Otherwise, late defects may present through the site of the incision in the external oblique aponeurosis (",
"    <a class=\"graphic graphic_figure graphicRef81116 \" href=\"mobipreview.htm?35/60/36814\">",
"     figure 10",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26505333\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial study using CST for closure of abdominal wall defects reported no recurrences in 11 patients followed for 4 months to 3.5 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/1\">",
"     1",
"    </a>",
"    ]. Subsequent retrospective reviews using open and endoscopic techniques have identified a wide range of hernia recurrence rates (1 to 53 percent) for patients followed for 1 to 7 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/7,8,13,18-21\">",
"     7,8,13,18-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective review of 3,028 recurrent ventral hernia repairs from a single institution database compared primary repair (n = 2383) with an adaptation of CST (n = 645), the sliding rectus abdominus myofascial repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/8\">",
"     8",
"    </a>",
"    ]. In the component repair, only the midline anterior rectus sheath was reinforced with a midline onlay mesh. There was no advancement of the posterior rectus sheath. The mean follow-up was 5.5 years. The important findings included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The failure rate following a primary repair was 38 percent.",
"     </li>",
"     <li>",
"      The failure rate following CST repair was 18 percent.",
"     </li>",
"     <li>",
"      The majority of recurrences (85 percent) were in the midline.",
"     </li>",
"     <li>",
"      Significant risk factors for recurrence included obesity, age greater than 65 years, male gender, postoperative seroma, and preoperative infection.",
"     </li>",
"     <li>",
"      There was no significant association between recurrence and type of mesh used in the midline onlay repair.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26505347\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Wound infections are the most common complication of CST hernia repair, ranging from 0 to 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/7,13,18\">",
"     7,13,18",
"    </a>",
"    ]. In a retrospective review of 354 patients, seromas and hematomas occurred in approximately 2 percent, and skin necrosis in approximately 1 percent of CST procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the only prospective trial comparing CST with a hernia repair using an e-PTFE patch, there was no significant difference in the rate of wound complications (53 versus 72 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32294/abstract/13\">",
"     13",
"    </a>",
"    ]. However, seven (39 percent) of the e-PTFE patches were removed secondary to wound complications, and the recurrences were repaired using CST.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25487972\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repair of a complex ventral hernia is challenging. Despite the relatively high frequency of recurrent abdominal wall incisional hernias, there is no consensus on the optimal repair. The component separation technique (CST) is an effective technique for reconstructing the abdominal wall in a manner that preserves innervated muscle function. (See",
"      <a class=\"local\" href=\"#H26505312\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with moderate to large (&gt;20 cm) midline or ventral hernias, we suggest using CST in combination with reinforcing materials, as needed, rather than primary fascial reapproximation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The use of reinforcing materials, such as prosthetic mesh or a biologic material, can help minimize tension in the repair. Recurrence rates following a ventral hernia repair using the CST procedure are significantly lower compared with the primary repair. (See",
"      <a class=\"local\" href=\"#H25488188\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endoscopically assisted CST repair is an alternative to the open technique. In a retrospective review that included seven patients repaired endoscopically, there were fewer wound infections (0 versus 40 percent wound infections), fewer midline ischemic wounds (0 versus 20 percent), and fewer wound dehiscences (0 versus 43 percent) compared with 30 patients undergoing traditional open CST. (See",
"      <a class=\"local\" href=\"#H7144726\">",
"       'Endoscopic assisted CST'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32294/abstract/1\">",
"      Ramirez OM, Ruas E, Dellon AL. \"Components separation\" method for closure of abdominal-wall defects: an anatomic and clinical study. Plast Reconstr Surg 1990; 86:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32294/abstract/2\">",
"      de Vries Reilingh TS, van Goor H, Rosman C, et al. \"Components separation technique\" for the repair of large abdominal wall hernias. J Am Coll Surg 2003; 196:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32294/abstract/3\">",
"      Shell DH 4th, de la Torre J, Andrades P, Vasconez LO. Open repair of ventral incisional hernias. Surg Clin North Am 2008; 88:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32294/abstract/4\">",
"      Sailes FC, Walls J, Guelig D, et al. Synthetic and biological mesh in component separation: a 10-year single institution review. Ann Plast Surg 2010; 64:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32294/abstract/5\">",
"      Shestak KC, Edington HJ, Johnson RR. The separation of anatomic components technique for the reconstruction of massive midline abdominal wall defects: anatomy, surgical technique, applications, and limitations revisited. Plast Reconstr Surg 2000; 105:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32294/abstract/6\">",
"      den Hartog D, Dur AH, Tuinebreijer WE, Kreis RW. Open surgical procedures for incisional hernias. Cochrane Database Syst Rev 2008; :CD006438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32294/abstract/7\">",
"      Lowe JB, Garza JR, Bowman JL, et al. Endoscopically assisted \"components separation\" for closure of abdominal wall defects. Plast Reconstr Surg 2000; 105:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32294/abstract/8\">",
"      Sailes FC, Walls J, Guelig D, et al. Ventral hernia repairs: 10-year single-institution review at Thomas Jefferson University Hospital. J Am Coll Surg 2011; 212:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32294/abstract/9\">",
"      Luijendijk RW, Hop WC, van den Tol MP, et al. A comparison of suture repair with mesh repair for incisional hernia. N Engl J Med 2000; 343:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32294/abstract/10\">",
"      DiBello JN Jr, Moore JH Jr. Sliding myofascial flap of the rectus abdominus muscles for the closure of recurrent ventral hernias. Plast Reconstr Surg 1996; 98:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32294/abstract/11\">",
"      Burger JW, Luijendijk RW, Hop WC, et al. Long-term follow-up of a randomized controlled trial of suture versus mesh repair of incisional hernia. Ann Surg 2004; 240:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32294/abstract/12\">",
"      Mathes SJ, Steinwald PM, Foster RD, et al. Complex abdominal wall reconstruction: a comparison of flap and mesh closure. Ann Surg 2000; 232:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32294/abstract/13\">",
"      de Vries Reilingh TS, van Goor H, Charbon JA, et al. Repair of giant midline abdominal wall hernias: \"components separation technique\" versus prosthetic repair : interim analysis of a randomized controlled trial. World J Surg 2007; 31:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32294/abstract/14\">",
"      Ramirez OM. Inception and evolution of the components separation technique: personal recollections. Clin Plast Surg 2006; 33:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32294/abstract/15\">",
"      van Eijck FC, de Blaauw I, Bleichrodt RP, et al. Closure of giant omphaloceles by the abdominal wall component separation technique in infants. J Pediatr Surg 2008; 43:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32294/abstract/16\">",
"      Nguyen V, Shestak KC. Separation of anatomic components method of abdominal wall reconstruction--clinical outcome analysis and an update of surgical modifications using the technique. Clin Plast Surg 2006; 33:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32294/abstract/17\">",
"      Maas SM, van Engeland M, Leeksma NG, Bleichrodt RP. A modification of the \"components separation\" technique for closure of abdominal wall defects in the presence of an enterostomy. J Am Coll Surg 1999; 189:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32294/abstract/18\">",
"      de Vries Reilingh TS, Bodegom ME, van Goor H, et al. Autologous tissue repair of large abdominal wall defects. Br J Surg 2007; 94:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32294/abstract/19\">",
"      Hood K, Millikan K, Pittman T, et al. Abdominal wall reconstruction: a case series of ventral hernia repair using the component separation technique with biologic mesh. Am J Surg 2013; 205:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32294/abstract/20\">",
"      Morris LM, LeBlanc KA. Components separation technique utilizing an intraperitoneal biologic and an onlay lightweight polypropylene mesh: \"a sandwich technique\". Hernia 2013; 17:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32294/abstract/21\">",
"      Eriksson A, Rosenberg J, Bisgaard T. Surgical treatment for giant incisional hernia: a qualitative systematic review. Hernia 2013.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15102 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-1A240FD273-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_34_32294=[""].join("\n");
var outline_f31_34_32294=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25487972\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26505312\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25488179\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25488188\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25488672\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25487965\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26505326\">",
"      PRINCIPLES OF THE SURGICAL TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25488798\">",
"      Preoperative assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25488810\">",
"      Intraoperative procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25488827\">",
"      Modifications of the technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7144726\">",
"      - Endoscopic assisted CST",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7144654\">",
"      - Abdominal wall atrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H262915984\">",
"      - Ostomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25488952\">",
"      - Reinforcing materials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26505333\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26505347\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25487972\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15102\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15102|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/1/34846\" title=\"figure 1\">",
"      Maximum dimensions of abdominal wall defect for CST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/40/29320\" title=\"figure 2\">",
"      Sectional view of the abdominal wall musculature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/5/28752\" title=\"figure 3\">",
"      Component separation technique skin flap dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?33/33/34320\" title=\"figure 4\">",
"      Component separation technique plane of dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/57/12191\" title=\"figure 5\">",
"      Component separation technique rectus muscle elevation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/0/29710\" title=\"figure 6\">",
"      Component separation technique and repaired defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/5/5215\" title=\"figure 7\">",
"      Endoscopic component separation technique rectus muscle release",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/20/31055\" title=\"figure 8\">",
"      Endoscopic component separation technique incision placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/10/30895\" title=\"figure 9\">",
"      Endoscopic component separation technique balloon insertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/60/36814\" title=\"figure 10\">",
"      Component separation technique with mesh",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39386?source=related_link\">",
"      Breast reconstruction in women with breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/0/11268?source=related_link\">",
"      Infection in mesh graft following hernia repair: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/49/43801?source=related_link\">",
"      Overview of abdominal hernias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/37/24151?source=related_link\">",
"      Parastomal hernia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14858?source=related_link\">",
"      Surgical management of sternal wound complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/14/43239?source=related_link\">",
"      Wound infections following abdominal wall hernia repair: Epidemiology, pathogenesis, and prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_34_32295="Nebivolol: Drug information";
var content_f31_34_32295=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nebivolol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/14/17637?source=see_link\">",
"    see \"Nebivolol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5580763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bystolic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5580767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta-Blocker, Beta-1 Selective",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5580937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 5 mg once daily; if initial response is inadequate, may be increased at 2-week intervals to a maximum dose of 40 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Heart failure (unlabeled use):",
"     </b>",
"     Adults &ge;70 years: Oral: Initial: 1.25 mg once daily; if tolerated, may increase by 2.5 mg at 1- to 2-week intervals to a maximum dose of 10 mg once daily (Flather, 2005).",
"     <b>",
"      Note:",
"     </b>",
"     Nebivolol has not been shown to reduce morbidity or mortality in the general HF population.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5580938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5580939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute): Initial: 2.5 mg/day; increase cautiously.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5580940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Moderate impairment (Child-Pugh class B): Initial: 2.5 mg/day; increase cautiously.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5581003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bystolic&reg;: 2.5 mg, 5 mg, 10 mg, 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5580765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F5580942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5580769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension, alone or in combination with other agents",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5580770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart failure",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5580781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (1%), bradycardia (&le;1%), chest pain (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (6% to 9%), fatigue (dose related; 2% to 5%), dizziness (2% to 4%), insomnia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: HDL levels decreased, hypercholesterolemia, triglyceride levels increased, uric acid levels increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (dose related; 2% to 3%), nausea (1% to 3%), abdominal pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Platelet count decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: BUN increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Acute pulmonary edema, acute renal failure, allergic vasculitis, angioedema, AST increased, ALT increased, AV block (second and third degree), bilirubin increased, bronchospasm, claudication, erectile dysfunction, hepatic function abnormal, hypersensitivity reaction, MI, peripheral ischemia, pruritus, psoriasis, Raynaud's phenomenon, skin disorder, somnolence, syncope, thrombocytopenia, urticaria, vertigo, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5580776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nebivolol or any component of the formulation; severe bradycardia; heart block greater than first-degree (except in patients with a functioning artificial pacemaker); cardiogenic shock; decompensated cardiac failure; sick sinus syndrome (unless a permanent pacemaker is in place); severe hepatic impairment (Child-Pugh class C)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5580777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to a variety of allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; for patients with bronchospastic disease who do not respond to or cannot tolerate other therapies, initial low doses of beta",
"     <sub>",
"      1",
"     </sub>",
"     -selective nebivolol may be employed and used cautiously with close monitoring. Ensure patient has an inhaled beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist immediately available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use with caution in patients with compensated HF and monitor for a worsening of the condition. If condition worsens, consider temporary discontinuation or dosage reduction of nebivolol. Patients should be stabilized on HF regimen prior to initiation of beta-blocker. Beta-blocker therapy should be initiated at very low doses with gradual and very careful titration. Adjustment of other medications (ACE inhibitors and/or diuretics) may be required.",
"     <b>",
"      Note:",
"     </b>",
"     Nebivolol has not been shown to reduce morbidity or mortality in the general HF population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment required with moderate impairment (Child-Pugh class B). Use is contraindicated in patients with Child-Pugh class C hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral vascular disease (PVD) and Raynaud's disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud's disease. Use with caution and monitor for progression of arterial obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psoriasis: Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment required with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute). Nebivolol has not been evaluated in dialysis-dependent patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium channel blockers: Use with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP2D6 Inhibitors: Use with caution in patients receiving CYP2D6 inhibitors (eg, chlorpromazine, fluoxetine, propafenone, propoxyphene, quinidine, ritonavir) (see Drug Interactions).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abrupt withdrawal: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with coronary artery disease), but gradually tapered over 1-2 weeks to avoid acute tachycardia, hypertension, and/or ischemia. Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F5580799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5580798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; FluvoxaMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Theophylline Derivatives.  Management: Monitor for reduced theophylline efficacy during concomitant use with any beta-blocker.  Beta-1 selective agents are less likely to antagonize theophylline than nonselective agents, but selectivity may be lost at higher doses.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5580802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice (may worsen hypertension). Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse (may increase antihypertensive effect).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5580771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5580772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in some animal reproduction studies; therefore, nebivolol is classified as pregnancy category C. In a cohort study, an increased risk of cardiovascular defects was observed following maternal use of beta-blockers during pregnancy. Intrauterine growth restriction (IUGR), small placentas, as well as fetal/neonatal bradycardia, hypoglycemia, and/or respiratory depression have been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth should be available. Untreated chronic maternal hypertension and pre-eclampsia are also associated with adverse events in the fetus, infant, and mother. Information related to the use of nebivolol for the treatment of hypertension in pregnancy has not been located; other agents may be more appropriate for use.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5580774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5580775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if nebivolol is excreted into breast milk. Breast-feeding is not recommended by the manufacturer due to potential for beta-blockers to produce serious effects on nursing infants, especially bradycardia.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5580941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5685503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Bystolic Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg (100): $267.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $267.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $267.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $81.49",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5580970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, ECG; serum glucose (in diabetic patients)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Hypoloc (DK, SE);",
"     </li>",
"     <li>",
"      Lobivon (GR, IT, NL);",
"     </li>",
"     <li>",
"      Lovispes (EE);",
"     </li>",
"     <li>",
"      Nabila (PE);",
"     </li>",
"     <li>",
"      Nebibeta (KP);",
"     </li>",
"     <li>",
"      Nebican (KP);",
"     </li>",
"     <li>",
"      Nebicar (PH);",
"     </li>",
"     <li>",
"      Nebicard (IN, PH);",
"     </li>",
"     <li>",
"      Nebilet (AR, AU, BG, CH, CN, CO, CR, CZ, DE, DO, EE, FI, GB, GT, HN, IE, KP, MY, NI, PA, PE, PL, PT, RU, SE, SG, SV, TH, VE, ZA);",
"     </li>",
"     <li>",
"      Nebilox (FR);",
"     </li>",
"     <li>",
"      Nebistar (IN);",
"     </li>",
"     <li>",
"      Nerispes (EE);",
"     </li>",
"     <li>",
"      Nobiten (BE);",
"     </li>",
"     <li>",
"      Temerit (FR);",
"     </li>",
"     <li>",
"      Zinebi (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5580805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Highly-selective inhibitor of beta",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic receptors; at doses &le;10 mg nebivolol preferentially blocks beta",
"     <sub>",
"      1",
"     </sub>",
"     -receptors. Nebivolol, unlike other beta-blockers, also produces an endothelium-derived nitric oxide-dependent vasodilation resulting in a reduction of systemic vascular resistance.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5580807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 8-12 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~98%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic; via glucuronidation and CYP2D6; extensive first-pass metabolism to multiple active metabolites with variable activity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: ~12% (extensive metabolizers); 96% (poor metabolizers)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Terminal: 10-12 hours (extensive metabolizers); 19-32 hours in poor metabolizers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 1.5-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (extensive metabolizers: 38%; poor metabolizers: 67%; &lt;0.5% of total dose as unchanged drug); feces (extensive metabolizers: 44%; poor metabolizers: 13%; &lt;0.5% of total dose as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brauchli YB, Jick SS, Curtin F, et al, &ldquo;Association Between Beta-Blockers, Other Antihypertensive Drugs and Psoriasis: Population-Based Case-Control Study,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 2008, 158(6):1299-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32295/abstract-text/18410416/pubmed\" id=\"18410416\" target=\"_blank\">",
"        18410416",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brixius K, Bundkirchen A, Bolck B, et al, &ldquo;Nebivolol, Bucindolol, Metoprolol and Carvedilol are Devoid of Intrinsic Sympathomimetic Activity in Human Myocardium,&rdquo;",
"      <i>",
"       Br J Pharmacol",
"      </i>",
"      , 2001, 133(8):1330-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32295/abstract-text/11498519/pubmed\" id=\"11498519\" target=\"_blank\">",
"        11498519",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cazzola M, Noschese P, D&rsquo;Amato M, Det al, &ldquo;Comparison of the Effects of Single Oral Doses of Nebivolol and Celiprolol on Airways in Patients With Mild Asthma,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2000, 118(5):1322-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32295/abstract-text/11083681/pubmed\" id=\"11083681\" target=\"_blank\">",
"        11083681",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cheymol G, Woestenborghs R, Snoeck E, et al. &ldquo;Pharmacokinetic Study and Cardiovascular Monitoring of Nebivolol in Normal and Obese Subjects,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1997, 51(6):493-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32295/abstract-text/9112066/pubmed\" id=\"9112066\" target=\"_blank\">",
"        9112066",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32295/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32295/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flather MD, Shibata MC, Coats AJ, et al, &ldquo;Randomized Trial to Determine the Effect of Nebivolol on Mortality and Cardiovascular Hospital Admission in Elderly Patients With Heart Failure (SENIORS),&rdquo;",
"      <i>",
"       Eur Heart J",
"      </i>",
"      , 2005, 26(3):215-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32295/abstract-text/15642700/pubmed\" id=\"15642700\" target=\"_blank\">",
"        15642700",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleisher LA, Beckman JA, Brown KA, et al, &ldquo;2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(22):e13-118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32295/abstract-text/19926002/pubmed\" id=\"19926002\" target=\"_blank\">",
"        19926002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fogari R, Zoppi A, Lazzari P, et al, &ldquo;Comparative Effects of Nebivolol and Atenolol on Blood Pressure and Insulin Sensitivity in Hypertensive Subjects With Type II Diabetes,&rdquo;",
"      <i>",
"       J Hum Hypertens",
"      </i>",
"      , 1997, 11(11):753-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32295/abstract-text/9416986/pubmed\" id=\"9416986\" target=\"_blank\">",
"        9416986",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32295/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Juul AB, Wetterslev J, Gluud C, et al, &ldquo;Effect of Perioperative Beta Blockade in Patients With Diabetes Undergoing Major Non-Cardiac Surgery: Randomized Placebo Controlled, Blinded Multicentre Trial. DIPOM Trial Group,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2006, 332(7556):1482.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32295/abstract-text/16793810/pubmed\" id=\"16793810\" target=\"_blank\">",
"        16793810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kamali F, Howes A, Thomas SHL, et al, &ldquo;A Pharmacokinetic and Pharmacodynamic Interaction Study Between Nebivolol and the H2-Receptor Antagonists Cimetidine and Ranitidine,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1997, 43(2):201-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32295/abstract-text/9131955/pubmed\" id=\"9131955\" target=\"_blank\">",
"        9131955",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32295/abstract-text/7669259/pubmed\" id=\"7669259\" target=\"_blank\">",
"        7669259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenauer PK, Pekow P, Wang K, et al, \"Perioperative Beta-Blocker Therapy and Mortality After Major Noncardiac Surgery,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 353(4):349-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32295/abstract-text/16049209/pubmed\" id=\"16049209\" target=\"_blank\">",
"        16049209",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nuttall SL, Routledge HC, and Kendall MJ, &ldquo;A Comparison of the Beta1&ndash;Selectivity of Three Beta1&ndash;Selective Beta-Blockers,&rdquo;",
"      <i>",
"       J Clin Pharm Ther",
"      </i>",
"      , 2003, 28(3):179-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32295/abstract-text/12795776/pubmed\" id=\"12795776\" target=\"_blank\">",
"        12795776",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patrianakos AP, Parthenakis FI, Mavrakis HE, et al, &ldquo;Comparative Efficacy of Nebivolol versus Carvedilol on Left Ventricular Function and Exercise Capacity in Patients With Non-Ischemic Cardiomyopathy. A 12-Month Study,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 2005, 150(5):985.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32295/abstract-text/16290981/pubmed\" id=\"16290981\" target=\"_blank\">",
"        16290981",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      POISE Study Group, Devereaux PJ, Yang H, et al, &ldquo;Effects of Extended-Release Metoprolol Succinate in Patients Undergoing Non-Cardiac Surgery (POISE Trial): A Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2008, 371(9627):1839-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32295/abstract-text/18479744/pubmed\" id=\"18479744\" target=\"_blank\">",
"        18479744",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prisant LM, &ldquo;Nebivolol: Pharmacologic Profile of an Ultraselective, Vasodilatory [Beta]1&ndash;Blocker,&rdquo;",
"      <i>",
"       J Clin Pharm",
"      </i>",
"      , 2008, 48(2):225-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32295/abstract-text/18083889/pubmed\" id=\"18083889\" target=\"_blank\">",
"        18083889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Redelmeier D, Scales D, and Kopp A, \"Beta Blockers for Elective Surgery in Elderly Patients: Population Based, Retrospective Cohort Study,\"",
"      <i>",
"       BMJ",
"      </i>",
"      , 2005, 331(7522):932.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32295/abstract-text/16210252/pubmed\" id=\"16210252\" target=\"_blank\">",
"        16210252",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sch&ouml;n MP and Boehncke WH, &ldquo;Psoriasis,&rdquo;",
"      <i>",
"       N Eng J Med",
"      </i>",
"      , 2005, 352(18):1899-1912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32295/abstract-text/15872205/pubmed\" id=\"15872205\" target=\"_blank\">",
"        15872205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32295/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      UK Prospective Diabetes Study Group, &ldquo;Efficacy of Atenolol and Captopril in Reducing Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 39,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1998, 317(7160):713-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32295/abstract-text/9732338/pubmed\" id=\"9732338\" target=\"_blank\">",
"        9732338",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yang H, Raymer K, Butler R, et al, &ldquo;The Effects of Perioperative Beta-Blockade: Results of the Metoprolol After Vascular Surgery (MaVS) Study, a Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Am Hear J",
"      </i>",
"      , 2006, 152(5):983-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32295/abstract-text/17070177/pubmed\" id=\"17070177\" target=\"_blank\">",
"        17070177",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9461 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-293D88DB16-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_34_32295=[""].join("\n");
var outline_f31_34_32295=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580763\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580767\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580937\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580938\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580939\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580940\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5581003\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580765\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580942\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580769\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580770\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580781\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580776\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580777\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580799\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580798\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580802\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580771\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580772\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580774\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580775\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580941\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5685503\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580970\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961934\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580805\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5580807\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9461\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9461|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?17/14/17637?source=related_link\">",
"      Nebivolol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_34_32296="Diazepam: Pediatric drug information";
var content_f31_34_32296=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diazepam: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"    see \"Diazepam: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/58/25509?source=see_link\">",
"    see \"Diazepam: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F159030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Diastat&reg;;",
"     </li>",
"     <li>",
"      Diastat&reg; AcuDial&trade;;",
"     </li>",
"     <li>",
"      Diazepam Intensol&trade;;",
"     </li>",
"     <li>",
"      Valium&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F159031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Diazepam&reg;;",
"     </li>",
"     <li>",
"      Bio-Diazepam;",
"     </li>",
"     <li>",
"      Diastat&reg;;",
"     </li>",
"     <li>",
"      Diazemuls&reg;;",
"     </li>",
"     <li>",
"      Diazepam Auto Injector;",
"     </li>",
"     <li>",
"      Diazepam Injection USP;",
"     </li>",
"     <li>",
"      Novo-Dipam;",
"     </li>",
"     <li>",
"      PMS-Diazepam;",
"     </li>",
"     <li>",
"      Valium&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1052159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antianxiety Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Benzodiazepine",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Benzodiazepine",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hypnotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sedative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Status epilepticus: I.V: (Not recommended as first-line agent; use only after multiple agents have failed; injection contains benzoic acid, sodium benzoate, and benzyl alcohol): 0.1-0.3 mg/kg/dose given over 3-5 minutes, every 15-30 minutes, to a maximum total dose of 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rectal gel formulation: Not recommended; product contains benzoic acid, sodium benzoate, benzyl alcohol, ethanol 10%, and propylene glycol; prolonged CNS depression has been reported in neonates receiving diazepam",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1052150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"      see \"Diazepam: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anxiety:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 0.12-0.8 mg/kg/day in divided doses every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., I.V.: 0.04-0.3 mg/kg/dose every 2-4 hours to a maximum of 0.6 mg/kg within an 8-hour period if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 2-10 mg 2-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., I.V.: 2-10 mg, may repeat in 3-4 hours if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Convulsive disorders:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adjunct: Adults: Oral: 2-10 mg 2-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Rectal gel formulation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants 1 to &lt;6 months: Not recommended; product contains benzoic acid, sodium benzoate, benzyl alcohol, ethanol 10%, and propylene glycol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants and Children 6 months to 2 years: Dose not established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 2-5 years: 0.5 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 6-11 years: 0.3 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &ge;12 years and Adults: 0.2 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Round dose to the nearest 2.5 mg increment, not exceeding a 20 mg/dose; dose may be repeated in 4-12 hours if needed; do not use more than 5 times per month or more than once every 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Rectal: Undiluted 5 mg/mL parenteral formulation (filter if using ampul): 0.5 mg/kg/dose then 0.25 mg/kg/dose in 10 minutes if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Febrile seizure prophylaxis: Children: Oral: 1 mg/kg/day divided every 8 hours; initiate therapy at first sign of fever and continue for 24 hours after fever resolves (Rosman, 1993; Steering Committee, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Status epilepticus:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &gt;30 days and Children: I.V: 0.1-0.3 mg/kg/dose given over 3-5 minutes, every 5&ndash;10 minutes (maximum: 10 mg/dose) (Hegenbarth, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer's recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Infants &gt;30 days and Children &lt;5 years: I.V: 0.2-0.5 mg slow I.V. every 2-5 minutes up to a maximum total dose of 5 mg; repeat in 2-4 hours if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &ge;5 years: I.V: 1 mg slow I.V. every 2-5 minutes up to a maximum of 10 mg; repeat in 2-4 hours if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adult: I.V:  Initial: 5-10 mg; may repeat every 10-15 minutes up to a maximum dose of 30 mg; may repeat in 2-4 hours if needed, but residual active metabolites may still be present",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ethanol withdrawal (acute):",
"     </b>",
"     Adults: Oral: 10 mg 3-4 times during first 24 hours, then decrease to 5 mg 3-4 times/day as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Muscle spasms:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cerebral palsy-associated spasticity:",
"     <b>",
"      Note:",
"     </b>",
"     Limited information exists; further studies are needed. Dose should be individualized and titrated to effect and tolerability. Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &lt;12 years and &lt;15 kg (Delgado, 2010; Mathew, 2005):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &lt;8.5 kg: 0.5-1 mg at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     8.5-15 kg: 1-2 mg at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 5-16 years and &ge;15 kg: Initial: 1.25 mg 3 times daily; may titrate to 5 mg 4 times daily (Engle, 1966)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     General muscle spasms: Adults: I.V., I.M.: Initial: 5-10 mg; then 5-10 mg in 3-4 hours, if necessary. Larger doses may be required if associated with tetanus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tetanus-associated:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants &gt;30 days: I.V., I.M.: 1-2 mg/dose every 3-4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;5 years: I.V., I.M.: 5-10 mg/dose every 3-4 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Preoperative medication:",
"     </b>",
"     Adults: I.M.: 10 mg before surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Sedation or muscle relaxation:",
"     </b>",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 0.12-0.8 mg/kg/day in divided doses every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V.: 0.04-0.3 mg/kg/dose every 2-4 hours to a maximum of 0.6 mg/kg within an 8-hour period if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate sedation for procedures:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oral: 0.2-0.3 mg/kg (maximum dose: 10 mg) 45-60 minutes prior to procedure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     I.V.: Initial: 0.05-0.1 mg/kg over 3-5 minutes, titrate slowly to effect (maximum total dose: 0.25 mg/kg) (Krauss, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oral: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     I.V.: 5 mg; may repeat with 2.5 mg if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Skeletal muscle relaxant (adjunct therapy):",
"     </b>",
"     Adults: Oral: 2-10 mg 3-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F159001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, rectal [adult rectal tip (6 cm)]: 20 mg (4 mL) [delivers set doses of 12.5 mg, 15 mg, 17.5 mg, 20 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diastat&reg; AcuDial&trade;: 20 mg (4 mL) [contains benzoic acid, benzyl alcohol, ethanol 10%, propylene glycol, sodium benzoate; 5 mg/mL (delivers set doses of 12.5 mg, 15 mg, 17.5 mg, and 20 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, rectal [pediatric rectal tip (4.4 cm)]: 5 mg/mL (0.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diastat&reg;: 5 mg/mL (0.5 mL) [contains benzoic acid, benzyl alcohol, ethanol 10%, propylene glycol, sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, rectal [pediatric/adult rectal tip (4.4 cm)]: 10 mg (2 mL) [delivers set doses of 5 mg, 7.5 mg, 10 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diastat&reg; AcuDial&trade;: 10 mg (2 mL) [contains benzoic acid, benzyl alcohol, ethanol 10%, propylene glycol, sodium benzoate; 5 mg/mL (delivers set doses of 5 mg, 7.5 mg, and 10 mg)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 5 mg/mL (2 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 5 mg/5 mL (5 mL, 500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [concentrate]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diazepam Intensol&trade;: 5 mg/mL (30 mL) [contains ethanol 19%, propylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 2 mg, 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Valium&reg;: 5 mg, 10 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Valium&reg;: 2 mg [scored; dye free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F158984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F159082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1052165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with food or water; do not administer with grapefruit juice. Oral concentrate solution (5 mg/mL): Measure dose only with calibrated dropper provided; dose should be diluted or mixed with water, juice, soda, applesauce, or pudding before use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.V.: Rapid injection may cause respiratory depression or hypotension; infants and children: Do not exceed 1-2 mg/minute I.V. push; adults: Maximum infusion rate: 5 mg/minute; maximum concentration for administration: 5 mg/mL. Avoid extravasation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rectal: Diastat&reg; AcuDial&trade;: Prior to administration, confirm that the syringe is properly set to the correct dose and that the green \"ready\" band is visible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Diastat&reg; AcuDial&trade; and Diastat&reg;: Place patient on side (facing person responsible for monitoring), with top leg bent forward. Insert rectal tip (lubricated) gently into rectum until rim fits snug against rectal opening; push plunger gently over 3 seconds. After additional 3 seconds, remove syringe; hold buttocks together while slowly counting to 3 to prevent leakage; keep patient on side, facing towards you and continue to observe patient; discard any unused medication, syringe, and all used materials safely away from children; do not reuse; see Administration and Disposal Instructions that come with product.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F159088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Per manufacturer, do not mix I.V. product with other medications.",
"     <b>",
"      Variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Dobutamine, fentanyl, methadone, morphine, nafcillin, quinidine gluconate, sufentanil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, atracurium, bivalirudin, cefepime, dexmedetomidine, diltiazem, doripenem, fenoldopam, fluconazole, foscarnet, heparin, heparin with hydrocortisone sodium succinate, hetastarch in lactate electrolyte injection (Hextend&reg;), linezolid, meropenem, oxaliplatin, pancuronium, pantoprazole, potassium chloride, propofol, tigecycline, tirofiban, vecuronium, vitamin B complex with C.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cisatracurium, hydromorphone, remifentanil.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Cimetidine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Dimenhydrinate, doxapram, glycopyrrolate, heparin, hydromorphone, ketamine, nalbuphine, pantoprazole, sufentanil.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ketorolac, lidocaine, meperidine, ranitidine.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1052154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light; potency is retained for up to 3 months when kept at room temperature; most stable at pH 4-8; hydrolysis occurs at pH &lt;3; do not mix injection with other medications",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral solution: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); dispense in light-resistant, tightly closed container",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral concentrated solution: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from light; discard opened bottle after 90 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); dispense in tightly closed, light-resistant container",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rectal gel: Store at 25&deg;C (77&deg;F); excursion permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1052164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Management of general anxiety disorders, ethanol withdrawal symptoms, relief of skeletal muscle spasms, muscle spasticity, and tetany; adjunct in the treatment of convulsive disorders (FDA approved in ages &ge;6 months and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Management of general anxiety disorders, ethanol withdrawal symptoms, relief of skeletal muscle spasms, muscle spasticity, and tetany; to provide preoperative or preprocedural sedation and amnesia; adjunct treatment of status epilepticus and severe recurrent convulsive disorders (FDA approved in ages &gt;30 days and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rectal gel: Management of intermittent bouts of increased seizure activity in refractory epilepsy patients on stable AED therapy (FDA approved in ages &ge;2 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F159090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Diazepam may be confused with diazoxide, diltiazem, Ditropan, LORazepam",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Valium&reg; may be confused with Valcyte&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F159087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reactions may vary by route of administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Hypotension, vasodilatation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Amnesia, ataxia, confusion, depression, drowsiness, fatigue, headache, slurred speech, paradoxical reactions (eg, aggressiveness, agitation, anxiety, delusions, hallucinations, inappropriate behavior, increased muscle spasms, insomnia, irritability, psychoses, rage, restlessness, sleep disturbances, stimulation), vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea, nausea, salivation changes (dry mouth or hypersalivation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Incontinence, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Phlebitis, pain with injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Dysarthria, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea, asthma, respiratory rate decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1052169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to diazepam or any component; possible cross-sensitivity with other benzodiazepines; do not use in a comatose patient, in those with pre-existing CNS depression, respiratory depression, acute narrow-angle glaucoma, severe uncontrolled pain, myasthenia gravis, severe respiratory insufficiency, severe hepatic insufficiency, or sleep apnea syndrome; oral dosage forms are listed by manufacturer as being contraindicated in patients &lt;6 months of age (due to lack of adequate clinical experience).",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1052149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients receiving other CNS depressants or psychoactive medication (effects with other sedative drugs or ethanol may be potentiated) and in patients with depression. Use with caution in patients with hypoalbuminemia, renal or hepatic dysfunction, and in neonates and young infants; neonates have decreased metabolism of diazepam and desmethyldiazepam (active metabolite), both can accumulate with repeated use and cause increased toxicity. Modify dosage in patients with hepatic impairment or chronic respiratory insufficiency, and in debilitated patients. Use with extreme caution in patients with a history of drug or alcohol abuse.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1052148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Abrupt discontinuation may cause withdrawal symptoms or seizures. Rapid I.V. push may cause sudden respiratory depression, apnea, hypotension, or cardiac arrest. Appropriate resuscitative equipment and qualified personnel should be available during parenteral administration with appropriate monitoring. Do not administer injection to patients in coma, shock, or acute ethanol intoxication with depression of vital signs. Tonic status epilepticus may occur in patients with petit mal status or petit mal variant status who are treated with diazepam. Administration of rectal gel should only be performed by individuals trained to recognize characteristic seizure activity for which the product is indicated and who are capable of monitoring patient's response to determine need for additional medical intervention.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Psychiatric and paradoxical reactions, including hyperactive or aggressive behavior, hallucinations, and psychoses, have been reported with benzodiazepines, particularly in adolescent/pediatric or elderly patients; discontinue diazepam if such reactions occur. Diazepam is not recommended for the treatment of psychotic patients, in place of appropriate therapy. Teratogenic effects have been reported in animal studies. In humans, diazepam crosses the placenta. An increased risk of congenital malformations and other developmental abnormalities have been associated with diazepam; epilepsy itself may also increase the risk. Hypotonia, hypothermia, withdrawal symptoms, and respiratory and feeding difficulties have been reported in the infant following maternal use of benzodiazepines near time of delivery.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Injection and rectal gel contain benzoic acid, benzyl alcohol, and sodium benzoate; benzyl alcohol may cause allergic reactions in susceptible individuals; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use diazepam products containing benzoic acid, benzyl alcohol, or sodium benzoate with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites. Parenteral formulation contains propylene glycol (40%) and alcohol (10%), which have been associated with toxicities when administered in high dosages or at rapid rates of infusion. Parenteral formulation, oral solution, concentrated oral liquid (Intensol&trade;), and rectal gel formulations contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use dosage forms containing propylene glycol with caution in neonates. Oral liquid products contain polyethylene glycol, which may have adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F159074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2B6 (minor), CYP2C19 (major), CYP2C9 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F158993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Benzodiazepines (metabolized by oxidation). Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cosyntropin: May enhance the hepatotoxic effect of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Moderate): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inhibitors (Strong): May decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May increase the serum concentration of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Diazepam. Etravirine may increase the serum concentration of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May increase the serum concentration of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation). Specifically, the active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Lansoprazole; Pantoprazole; RABEprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: May increase the serum concentration of Diazepam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; PARoxetine; Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1052172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Grapefruit juice significantly increases oral bioavailability of diazepam. Food may delay and decrease oral absorption.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F158996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F159013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been reported in animal studies. In humans, diazepam and its metabolites (N-desmethyldiazepam, temazepam, and oxazepam) cross the placenta. Teratogenic effects have been observed with diazepam; however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) has been reported with some benzodiazepines (including diazepam).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1052158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, respiratory rate, blood pressure, mental status; with long-term therapy: Liver enzymes, CBC",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1052163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Effective therapeutic range not well established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Proposed therapeutic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diazepam: 0.2-1.5 mcg/mL (SI: 0.7-5.3 micromoles/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     N-desmethyldiazepam (nordiazepam): 0.1-0.5 mcg/mL (SI: 0.35-1.8 micromoles/L)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1052147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Depresses all levels of the CNS, including the limbic and reticular formation by binding to the benzodiazepine site on the gamma-aminobutyric acid (GABA) receptor complex and modulating GABA, which is a major inhibitory neurotransmitter in the brain",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1052167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Status epilepticus:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 1-3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal: 2-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 15-30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1052168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 85% to 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: Poor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal (gel): Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributed; crosses blood-brain barrier and placenta; distributes into breast milk; V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 0.8-1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 84% to 86%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver to desmethyldiazepam (active metabolite) and N-methyloxazepam (active metabolite); these are metabolized to oxazepam (active) which undergoes glucuronide conjugation before being excreted",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Rectal (gel): 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diazepam:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Neonates: 50-95 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants 1 month to 2 years: 40-50 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 2-12 years: 15-21 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 12-16 years: 18-20 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 20-50 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Increased half-life in those with severe hepatic disorders",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Desmethyldiazepam (active metabolite): Adults: 50-100 hours; may be further prolonged in neonates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Mean: 1-1.5 hours; range: 0.25-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal (gel): 1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine, primarily as conjugated oxazepam (75%), desmethyldiazepam, and N-methyloxazepam",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not dialyzable (0% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1052156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/58/25509?source=see_link\">",
"      see \"Diazepam: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol and grapefruit juice; limit caffeine. May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. May be habit-forming; avoid abrupt discontinuation after prolonged use",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1052170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Diazepam does not have any analgesic effects. Diarrhea in a 9 month old infant receiving high-dose oral diazepam was attributed to the diazepam oral solution that contained polyethylene glycol and propylene glycol (both are osmotically active); diarrhea resolved when crushed tablets were substituted for the oral solution (Marshall, 1995).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Diastat&reg; AcuDial&trade;: Prescribed dose must be \"dialed in\" and locked before dispensing; consult package insert for directions on setting prescribed dose; confirm green \"ready\" band is visible prior to dispensing product.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review),\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32296/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics; American Academy of Pediatric Dentistry, Cot&eacute; CJ, et al, \"Guidelines for Monitoring and Management of Pediatric Patients During and After Sedation for Diagnostic and Therapeutic Procedures: An Update,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2006, 118(6):2587-602.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32296/abstract-text/17142550/pubmed\" id=\"17142550\" target=\"_blank\">",
"        17142550",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Delgado MR, Hirtz D, Aisen M, et al, \"Practice Parameter: Pharmacologic Treatment of Spasticity in Children and Adolescents With Cerebral Palsy (An Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2010, 74(4):336-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32296/abstract-text/20101040/pubmed\" id=\"20101040\" target=\"_blank\">",
"        20101040",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dreifuss FE, Rosman NP, Cloyd JC, et al, &ldquo;A Comparison of Rectal Diazepam Gel and Placebo for Acute Repetitive Seizures,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(26):1869-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32296/abstract-text/ 9637805 /pubmed\" id=\" 9637805 \" target=\"_blank\">",
"        9637805",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Engle HA, \"The Effect of Diazepam (Valium) in Children With Cerebral Palsy: A Double-Blind Study,\"",
"      <i>",
"       Dev Med Child Neurol",
"      </i>",
"      , 1966, 8(6):661-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32296/abstract-text/5339679/pubmed\" id=\"5339679\" target=\"_blank\">",
"        5339679",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, \"Preparing for Pediatric Emergencies: Drugs to Consider,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32296/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krauss B and Green SM, \"Procedural Sedation and Analgesia in Children,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2006, 367(9512):766-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32296/abstract-text/16517277/pubmed\" id=\"16517277\" target=\"_blank\">",
"        16517277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marshall JD, Farrar HC, and Kearns GL, &ldquo;Diarrhea Associated With Enteral Benzodiazepine Solutions,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1995, 126(4):657-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32296/abstract-text/7699551/pubmed\" id=\"7699551\" target=\"_blank\">",
"        7699551",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mathew A, Mathew MC, Thomas M, et al, \"The Efficacy of Diazepam in Enhancing Motor Function in Children With Spastic Cerebral Palsy,\"",
"      <i>",
"       J Trop Pediatr",
"      </i>",
"      , 2005, 51(2):109-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32296/abstract-text/15840761/pubmed\" id=\"15840761\" target=\"_blank\">",
"        15840761",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosman NP, Colton T, Labazzo J, et al, &ldquo;A Controlled Trial of Diazepam Administered During Febrile Illnesses to Prevent Recurrence of Febrile Seizures,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(2):79-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32296/abstract-text/8510706 /pubmed\" id=\"8510706 \" target=\"_blank\">",
"        8510706",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, \"Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32296/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zeltzer LK, Altman A, Cohen D, et al, &ldquo;Report of the Subcommittee on the Management of Pain Associated With Procedures in Children With Cancer,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1990, 86(5 Pt 2):826-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/34/32296/abstract-text/2216645/pubmed\" id=\"2216645\" target=\"_blank\">",
"        2216645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13223 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-D1AB04EF24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_34_32296=[""].join("\n");
var outline_f31_34_32296=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159030\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159031\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052159\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442291\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052150\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159001\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158984\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159082\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052165\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159088\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052154\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052164\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159090\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159087\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052169\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052149\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052148\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159074\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158993\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052172\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158996\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159013\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052158\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052163\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052147\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052167\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052168\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052156\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052170\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13223\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13223|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=related_link\">",
"      Diazepam: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/58/25509?source=related_link\">",
"      Diazepam: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_34_32297="Holter of monomorphic VT";
var content_f31_34_32297=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54513&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Sustained ventricular tachycardia on ambulatory monitoring",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 388px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ambulatory monitor in a patient being evaluated for syncope, which persisted after pacemaker insertion, shows sustained monomorphic ventricular tachycardia (SMVT) which terminates spontaneously. A brief period of ventricular pacing follows ventricular tachycardia termination.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission by Samuel Levy, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_34_32297=[""].join("\n");
var outline_f31_34_32297=null;
var title_f31_34_32298="Urinary diversion and reconstruction following cystectomy";
var content_f31_34_32298=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Urinary diversion and reconstruction following cystectomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/34/32298/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/34/32298/contributors\">",
"     Shahrokh F Shariat, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/34/32298/contributors\">",
"     Bernard H Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/34/32298/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/34/32298/contributors\">",
"     Seth P Lerner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/34/32298/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/34/32298/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/34/32298/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Removal of the bladder (cystectomy) necessitates reconstruction of the lower urinary tract. Bladder cancer is the most common reason for cystectomy. However, the same principles apply to patients who undergo pelvic exenteration for other malignancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/1,2\">",
"     1,2",
"    </a>",
"    ] or who require cystectomy for non-malignant conditions, such as birth defects, trauma, or neurologic disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/39/634?source=see_link\">",
"     \"Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ureterosigmoidostomy was the first widely used surgical technique for urinary diversion, providing an effective diversion that relied upon the anal sphincter for continence. However, deterioration of renal function over time, metabolic complications, and the increased risk for the development of secondary malignancies limited its usefulness. Subsequent surgical advances in reconstructive techniques have led to major improvements in both functional outcomes and quality of life.",
"   </p>",
"   <p>",
"    Here we will discuss the available reconstructive options after cystectomy, the criteria for selection of the most appropriate procedure, and the outcomes and complications associated with the different urinary diversions. The indications for and complications of cystectomy in patients with bladder cancer are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/39/634?source=see_link\">",
"     \"Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general principle, any segment of bowel can be used to form a urinary diversion. However, there are metabolic consequences associated with the utilization of each segment based upon the absorptive function of bowel (",
"    <a class=\"graphic graphic_table graphicRef63267 \" href=\"mobipreview.htm?29/60/30669\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/4-20\">",
"     4-20",
"    </a>",
"    ]. In addition, the length and location of bowel segment used can affect the patient's postoperative bowel function.",
"   </p>",
"   <p>",
"    Ureterosigmoidostomy was the first widely used surgical approach for urinary diversion after cystectomy. With this technique, the ureters were implanted into the sigmoid colon and the anal sphincters were relied upon to provide continence. Approximately 50 years of experience with this approach defined a series of complications that guided subsequent surgical progress:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gradual deterioration of renal function, secondary both to chronic urinary tract infection, which was a result of mixing of the urinary and fecal streams, and to obstruction of the ureterointestinal anastomosis",
"     </li>",
"     <li>",
"      Normal anion gap (hyperchloremic) metabolic acidosis, as a result of resorption of excreted urinary products by the bowel mucosa (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29589?source=see_link\">",
"       \"Acid-base and electrolyte abnormalities with diarrhea or ureteral diversion\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Development of secondary cancers in the sigmoid colon near the site of ureteral implantation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While technical advances in urinary tract reconstruction have lessened these complications, the ideal urinary diversion has yet to be developed (",
"    <a class=\"graphic graphic_table graphicRef54033 \" href=\"mobipreview.htm?6/60/7115\">",
"     table 2",
"    </a>",
"    ). Nevertheless, substantial progress has been made by incorporating innovative techniques that use isolated bowel segments as either urinary conduits or continent reservoirs. Most recently, the creation of continent cutaneous diversions and the development of internal reservoirs connected to the native urethra have improved quality of life and patient acceptance by permitting volitional voiding. As a result, patients undergoing cystectomy now have several options for urinary diversion, all of which rely upon the use of an intervening bowel segment.",
"   </p>",
"   <p>",
"    Reconstructive procedures fall into two general categories: incontinent diversions, such as the ileal conduit to the skin surface, and continent reconstructions, which include both cutaneous reservoirs and reservoirs connected to the urethra. With the ileal loop conduit, urine is directed from the ureters through a segment of isolated ileum to the surface of the abdominal wall. There it continually drains, requiring an external appliance on the skin surface for urine collection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/21\">",
"     21",
"    </a>",
"    ]. In contrast, continent reservoirs collect and store the urine internally and are intermittently emptied either by catheterization or volitional voiding, freeing the patient from the need for an external appliance.",
"   </p>",
"   <p>",
"    Two distinct approaches to continent reconstructions are utilized, cutaneous diversions and orthotopic neobladders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a continent cutaneous reservoir, the bowel segment is connected to the skin through a surgically created stoma on the abdominal wall, which must be catheterized periodically to empty the urine.",
"     </li>",
"     <li>",
"      In contrast, an orthotopic neobladder utilizes an intestinal segment that is anastomosed to an intact urethra. This procedure allows the patient to void volitionally through the urethra, restoring a more natural voiding pattern. This technique is available for properly selected men and women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The orthotopic neobladder has become the procedure of choice for suitably selected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. However, continent cutaneous reservoirs and ileal conduits remain important options and may be the most appropriate diversion in selected circumstances.",
"   </p>",
"   <p>",
"    The following is a brief overview of the most common techniques used for urinary diversion and their specific complications, followed by a discussion of factors that are considered in selecting one technique over another.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ILEAL CONDUITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ileal conduits were the gold standard for urinary reconstruction until the introduction and subsequent acceptance of continent diversions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/24\">",
"     24",
"    </a>",
"    ]. The ileal conduit remains the procedure of choice for patients with a short life expectancy, and for those who cannot complete the rehabilitation and subsequently manage a continent diversion. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Orthotopic neobladders'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Due to the relative ease of its formation and the shorter operative time, an ileal conduit is often used in patients with significant medical comorbidities in an attempt to minimize postoperative complications and the risk of reoperation. The terminal 10 to 15 cm of ileum at the ileocecal junction is typically preserved to maintain adequate absorption of bile salts, vitamin B12, and fat-soluble vitamins. The isolated ileal segment then serves as a mere conduit for urine to drain from kidneys to the exterior in a bag secured to an appliance.",
"   </p>",
"   <p>",
"    The segment of ileum is exteriorized in the form of a stoma through the abdominal wall, around which an appliance is secured and into which urine continuously drains. The presence of this stoma and appliance does affect a patient's body image. In obese patients, where a short bowel mesentery and thick abdominal wall may prevent the creation of an end-on stoma without undue tension, a loop type of stoma (Turnbull) is commonly advocated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Long-term outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ileal conduits have been used for many years, and detailed information is available regarding the incidence of complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/24,26,27\">",
"     24,26,27",
"    </a>",
"    ]. One study of 131 patients who underwent ileal conduit reconstruction and survived at least five years demonstrated an overall complication rate of 66 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/24\">",
"     24",
"    </a>",
"    ]. Many patients experienced more than one complication during the first five years, and complications continued to develop even beyond 15 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty-four percent developed problems with the stoma (eg, stenosis, parastomal hernia, bleeding, skin irritation).",
"     </li>",
"     <li>",
"      Bowel complications occurred in 24 percent, predominantly obstruction, although enterocutaneous fistulas were also observed.",
"     </li>",
"     <li>",
"      Urinary tract infection requiring hospitalization occurred in 23 percent and was usually associated with postrenal obstruction due to anastomotic stricture, stomal stenosis, or stones. Urolithiasis developed in 9 percent.",
"     </li>",
"     <li>",
"      Fourteen percent developed stenosis requiring open or endoscopic surgical correction at the ureteral conduit junction.",
"     </li>",
"     <li>",
"      Deterioration of renal function was observed in 27 percent, while hyperchloremic acidosis developed in only 2 percent. A similar rate of deterioration of renal function was observed in another series of 178 patients, all of whom had at least four years of follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these rates of long term complications seem high compared with those reported following orthotopic neobladder reconstruction, it is difficult to draw definitive conclusions. Surgical techniques have improved markedly over the last 25 years, and few data report comparable long-term outcomes (&gt;20 years) in patients with orthotopic neobladders. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Orthotopic neobladders'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CONTINENT CUTANEOUS DIVERSIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All continent cutaneous reservoirs rely upon a low-pressure pouch constructed of various detubularized bowel segments and a functional mechanism that connects the reservoir to the skin, designed to prevent involuntary urine flow. Reservoirs differ based upon the type of valve mechanism constructed and the exact segment of intestine utilized. Many technical variations exist; examples include the Kock, Indiana, and Miami pouches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. The most obvious advantages of this type of diversion are the ability to avoid continuous urine drainage and the need for an external appliance.",
"   </p>",
"   <p>",
"    These continent cutaneous diversions require intermittent clean self-catheterization through the stoma both to empty the reservoir and to irrigate mucous. No stomal appliance is usually required. The importance of the ability of the patient to catheterize the stoma and be motivated to do this lifelong cannot be overemphasized before offering this form of diversion.",
"   </p>",
"   <p>",
"    Although continent cutaneous diversions have been largely supplanted by the orthotopic neobladder, this procedure is used when the urethra or bladder neck is non-functional or involved by tumor, and avoidance of an external appliance is desired. Patient education and motivation are required to manage the stoma and perform the necessary self-catheterization successfully [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of studies have demonstrated the safety and functional benefits of continent cutaneous diversions; however, complication rates can be significant. Problems associated with the stoma, including difficulties with catheterization and urinary leakage, have been reported in a significant percentage of patients. Urinary leakage can result from either too high a pressure within the reservoir or inadequate resistance to flow at the level of the valve mechanism. Additional problems include stone formation within the pouch and urinary tract infections, which are observed in up to 20 percent.",
"   </p>",
"   <p>",
"    Results have varied in different institutions. For example, in a report of 112 patients receiving a modified Indiana pouch at a single institution over a 14 year period, 90 percent experienced complications at some point [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/32\">",
"     32",
"    </a>",
"    ]. Incontinence (any leakage) was most common (28 percent), while complications related to the efferent loop of the pouch included stomal stenosis (15 percent) and difficulty in catheterization (10 percent). Other problems included ureteral anastomotic strictures (7 percent), gallstones (26 percent), kidney stones (6 percent), stones within the pouch (10 percent), and small bowel obstruction (5 percent). Reoperation was required in 21 percent, mostly for stomal stenosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40802?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis and clinical manifestations of struvite stones\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternative pouch designs, particularly using the in situ appendix as the continence mechanism and catheterizable limb, have reported improved outcomes with a lower rate of major complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/33\">",
"     33",
"    </a>",
"    ]. Reports using this mechanism or its modifications in previously radiated patients suggest that improved outcomes can be achieved using appropriate design alterations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ORTHOTOPIC NEOBLADDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthotopic neobladders are internal reservoirs that are connected to the native urethra and rely upon the external striated sphincter for continence. These reservoirs are constructed from a segment of detubularized intestine (usually ileum) anastomosed to the native urinary outflow tract.",
"   </p>",
"   <p>",
"    Orthotopic neobladders were initially limited to men. In women, urethra-sparing orthotopic substitution was thought to be associated with an increased risk of local recurrence and voiding dysfunction. However, as our understanding of the female rhabdoid sphincteric (continence) mechanism has improved, this approach has become technically feasible in women, and oncologic outcomes are not compromised [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/36\">",
"     36",
"    </a>",
"    ]. Because this approach facilitates the restoration of normal self-image by approximating normal voiding, construction of an orthotopic neobladder has become the procedure of choice for most patients following cystectomy for bladder cancer in both men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Appropriate patient selection is critical to the success of this approach. The creation of an orthotopic neobladder should not compromise potentially curative cancer surgery, and it is contraindicated if the urethra is nonfunctional or involved with tumor. In addition, orthotopic neobladders require active patient participation to ensure the return of full control of urination and maintenance of the reservoir. If medical or psychosocial issues preclude this level of cooperation, the patient may be better served by a noncontinent ileal loop diversion. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Factors influencing choice of procedure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Role of anti-reflux anastomosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some neobladders (eg, the hemi-Kock) incorporate an anti-reflux mechanism to limit backflow of urine from the reservoir into the upper urinary tracts. Although this approximates the normal anti-reflux apparatus of the native bladder, the need for this approach is controversial.",
"   </p>",
"   <p>",
"    Proponents cite the detrimental upper tract changes that develop in patients who are followed for 10 years or longer after ileal conduits or ureterosigmoidostomy, both of which are associated with freely refluxing infected urine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/37-40\">",
"     37-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, the need for specific antireflux maneuvers has been questioned for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Long-term complications of reflux with orthotopic neobladders have been predominantly seen in patients who have high-pressure reservoirs. Contemporary neobladder designs employ detubularized bowel segments that are configured to provide low filling pressures.",
"     </li>",
"     <li>",
"      Voiding pressures within orthotopic neobladders are generated via the Valsalva maneuver and exerted to all of the intraabdominal contents including the ureters and renal pelvis. This equal pressure distribution minimizes reflux during voiding. In addition, some neobladder designs (eg, the Studer reservoir) utilize a long isoperistaltic proximal limb, which provides resistance to retrograde flow, thereby providing additional antireflux protection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. Long-term follow-up of patients with neobladders that do not incorporate an anti-reflux design have confirmed that reflux-related complications are rare.",
"     </li>",
"     <li>",
"      Ureteral anastomoses that are designed to prevent reflux may lead to a greater risk of complications (eg, ureteroenteric stricture, ischemic fibrosis of the antireflux valve, stone formation from staples used to construct the valve system), which contribute substantially to morbidity. In one retrospective comparison of 60 patients, stricture formation in patients with tunneled (antireflux) ureters was significantly more common compared to that in those with a direct anastomosis (13 versus 1.7 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/43\">",
"       43",
"      </a>",
"      ]. The higher rate of stricture formation was not counterbalanced by significant decreases in the incidence of hydronephrosis, pyelonephritis, stones, or azotemia. Similarly, in a randomized trial of 60 patients, construction of a nonrefluxing anastomosis was associated with a higher incidence of anastomotic strictures and secondary impairment of renal function compared to a direct anastomosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Functional outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The functional goals of an orthotopic neobladder are to maintain continence during both the day and night and to allow consistent emptying of the neobladder without the need for intermittent catheterization. Comparison of functional outcomes data is complicated by variability in the definition of continence, whether it is assessed by the physician or patient, and the time frame of assessment relative to surgery.",
"   </p>",
"   <p>",
"    In several large series comprised predominantly of men, daytime and nighttime continence rates ranged from 87 to 100 percent, and 70 to 95 percent, respectively (",
"    <a class=\"graphic graphic_table graphicRef70451 \" href=\"mobipreview.htm?3/34/3629\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Continence rates improve gradually postoperatively, as the neobladder volume increases. In most patients, maximal control of voiding requires several months. As an example, in a series of 86 men, 61 percent were continent at three months, increasing to 92 percent at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/45\">",
"     45",
"    </a>",
"    ]. In another series of 166 patients, nighttime continence rates were 75 and 94 percent at years one and three, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other patterns emerging from these series included the observation that daytime continence returns more rapidly than nighttime continence and that continence rates in individuals over age 70 are lower than in younger patients.",
"   </p>",
"   <p>",
"    Inadequate emptying of the neobladder in men is uncommon. The frequency and etiology of this complication was illustrated in a single institution series of 655 men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/46\">",
"     46",
"    </a>",
"    ]. Inadequate emptying (defined as a residual volume &gt;100 mL) was observed in 75 cases (11.5 percent). In 52 patients, this was due to mechanical obstruction, most commonly either benign strictures of the neovesicourethral anastomosis or local tumor recurrence; in 38 of these cases bladder emptying was restored with a local urological procedure, while 14 required some form of long-term catheterization. In the 23 cases without a mechanical obstruction, failure of bladder emptying was dysfunctional and intermittent or indwelling catheterization was required.",
"   </p>",
"   <p>",
"    For women, daytime continence rates were also very high (75 to 93 percent), at average follow-up durations of 20 to 33 months; nighttime rates were similar to men at 72 to 84 percent (",
"    <a class=\"graphic graphic_table graphicRef82635 \" href=\"mobipreview.htm?38/5/39003\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/47-51\">",
"     47-51",
"    </a>",
"    ]. One significant difference observed in women was the more frequent need to perform intermittent catheterization, which ranged from 11 to 70 percent. The increased rate of needing intermittent catheterization (\"hypercontinence\") in woman is thought to be due in part to a posterior prolapse of the neobladder during Valsalva voiding. Techniques that have improved the anterior and posterior support of the neobladder have led to improved functional outcomes.",
"   </p>",
"   <p>",
"    In summary, attention to neobladder design, careful surgical technique, appropriate patient selection, and patient education all contribute to optimizing functional results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/26,52\">",
"     26,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Oncologic outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preservation of the urethra in patients with urothelial tumors in order to construct an orthotopic neobladder raises concerns about possible recurrence of cancer, since the transitional cell lining of the urethra may be particularly susceptible to the development of new tumors in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Men",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, the risk for developing a urethral recurrence following cystectomy was between 6 and 10 percent; however, surgical series of patients whose urinary stream has been diverted through the urethra have a lower than expected recurrence rate, despite the retention of the urethra. In some series, this has been observed even in men with involvement of the prostatic urethra, a subset at particularly high risk.",
"   </p>",
"   <p>",
"    This is illustrated by several studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 196 men undergoing cystoprostatectomy and orthotopic urinary diversion, only one had a urethral recurrence despite the finding of microscopic involvement of the prostatic urethra in 13 and foci of carcinoma in situ (CIS) in 83 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On the other hand, others report a higher risk of urethral recurrence with both superficial (prostatic urethra or prostatic ducts alone) or invasive (prostatic stroma) prostate involvement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/54,55\">",
"       54,55",
"      </a>",
"      ]. In a series of 768 consecutive men undergoing cystectomy and urinary reconstruction, the urethral recurrence rate in the absence of prostatic involvement was 5 percent, and for those with superficial or invasive prostate involvement, it was 12 and 18 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar results were noted in another report of 174 men receiving orthotopic neobladders for bladder cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/55\">",
"       55",
"      </a>",
"      ]. The five-year rate of local recurrence with no prostate involvement was 6 percent, while for those with superficial or invasive prostate involvement, the rates were 15 and 21 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are more limited, oncologic outcomes in women appear to be similar to those in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/51,56,57\">",
"     51,56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 145 women with negative margins on frozen section at the time of cystectomy, only two (1.4 percent) developed isolated urethral recurrence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A series of 201 women undergoing radical cystectomy for bladder cancer included 120 with orthotopic neobladder and 81 with cutaneous diversion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/51\">",
"       51",
"      </a>",
"      ]. For the patients managed with an orthotopic neobladder, the 5 and 10 year recurrence free survival rates were 62 and 55 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of surveillance programs (ie, urethral wash cytology) to monitor for urethral recurrence following cystectomy is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/58\">",
"     58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some studies have not demonstrated a difference in clinical outcome in screened patients compared to those followed clinically [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/59,60\">",
"       59,60",
"      </a>",
"      ]. As an example, in a series of 176 men undergoing cystoprostatectomy with urinary diversion, urethral recurrence was documented in 13 of 48 monitored individuals (10 of whom underwent urethrectomy), and 16 of 128 patients who were followed clinically, all of whom underwent urethrectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/59\">",
"       59",
"      </a>",
"      ]. There was no difference in the rate of disease progression regardless of the method of diagnosis.",
"     </li>",
"     <li>",
"      On the other hand, proponents of surveillance argue that earlier diagnosis of an asymptomatic urethral recurrence provides a better chance for curative urethrectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/61\">",
"       61",
"      </a>",
"      ]. A poorer outcome in patients with more advanced urethral recurrences has been demonstrated, strongly supporting the use of techniques to detect recurrent disease at an early stage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors routinely monitor urethral cytologies following cystectomy, particularly in patients at high risk (ie, those with CIS or any prostatic involvement at the time of cystectomy).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the primary reasons for choosing an orthotopic neobladder over continent cutaneous diversion is the maintenance of normal body image and function. Conversely, continent cutaneous diversion may offer a significantly better quality of life (QOL) compared to an orthotopic neobladder with respect to social dryness.",
"   </p>",
"   <p>",
"    While some reports have noted improvements in various aspects of quality of life (QOL) (eg, body image) using these reconstructive techniques, few formal studies have been undertaken to document an improvement in overall QOL. Most have failed to confirm superior outcomes in patients undergoing orthotopic neobladder reconstruction as opposed to other forms of reconstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/63-67\">",
"     63-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several examples illustrate the disparate findings in these studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One series analyzed health status questionnaires from 29 patients with an ileal loop conduit and 42 with an orthotopic neobladder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/63\">",
"       63",
"      </a>",
"      ]. Although there were advantages in QOL for those receiving an orthotopic neobladder, these patients were younger, and the observed differences could have been age-related.",
"     </li>",
"     <li>",
"      Another study compared 69 patients with an orthotopic neobladder and 33 with an ileal conduit following bladder cancer surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/64\">",
"       64",
"      </a>",
"      ]. Patients with an orthotopic neobladder had better QOL, based upon their perception of being handicap-free and incontinence-free. When asked, 97 percent would recommend the procedure to others, compared to only 36 percent of the ileal conduit patients.",
"     </li>",
"     <li>",
"      In a series of 80 men undergoing cystectomy for bladder cancer, there were no significant differences in overall QOL when patients with a continent cutaneous diversions were compared to those with orthotopic neobladders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/66\">",
"       66",
"      </a>",
"      ]. While men with a continent diversion had fewer problems managing urine, those with a neobladder were more likely to retain erectile function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A systematic overview of 15 published studies (only one prospective, none randomized) examining health-related QOL (HR-QOL) after radical cystectomy and urinary diversion for bladder cancer concluded that the available data were insufficient to conclude that any one form of urinary diversion was associated with a better QOL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/68\">",
"     68",
"    </a>",
"    ]. The authors identified the lack of preoperative (baseline) assessment, the lack of longitudinal studies using valid and reliable measures, and the absence of a validated instrument to measure bladder cancer-specific HR-QOL as major limitations.",
"   </p>",
"   <p>",
"    The assessment of QOL after urinary diversion has improved greatly over the past decade. The development of bladder cancer-specific instruments has been essential in detecting differences in urinary, bowel, sexual, and body image outcomes in bladder cancer survivors. As these instruments become validated in prospective longitudinal studies, there will be enhanced knowledge about the recovery and related impact on QOL in this population.",
"   </p>",
"   <p>",
"    Currently, orthotopic diversion does not provide overwhelming or major QOL benefit compared to an incontinent cutaneous diversion. However, orthotopic diversion certainly may be the better for selected patients, irrespective of age. Psychological adaptation to physical changes should not be underestimated, potentially explaining the very similar QOL states that patients have one year after surgical treatment. Nontraditional methods of comparative research may ultimately demonstrate that the diversion class is not the defining factor in QOL after diversion. Instead, other patient, social, or process factors may control long-term outcomes.",
"   </p>",
"   <p>",
"    Understanding population differences and creating instruments with adequate sensitivity to discern these differences will be necessary to better understand the true global nature of QOL and optimize diversion satisfaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     FACTORS INFLUENCING CHOICE OF PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detailed evaluations of patients' medical, physical, and psychological status, as well as their support systems, are required prior to selection of the appropriate urinary diversion procedure. The decision requires consideration of surgical, oncologic, medical, and psychosocial issues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most commonly used urinary diversions utilize the distal ileum",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cecum along with ascending or sigmoid colon, because these sites have the fewest metabolic consequences. Electrolyte and metabolic abnormalities differ based upon the bowel segment used for the diversion. While most metabolic abnormalities are clinically subtle, they may assume significance in patients with renal insufficiency and in adolescents and young adults who will be subjected to the metabolic abnormalities for a prolonged period. The primary indications for the use of various bowel segments and the associated metabolic consequences and symptomatology are shown in the following table (",
"    <a class=\"graphic graphic_table graphicRef63267 \" href=\"mobipreview.htm?29/60/30669\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/18,70-73\">",
"     18,70-73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary goals in selecting a urinary diversion are to provide the patient with a diversion that results in the best local cancer control, the lowest potential for short and long-term complications, and the best quality of life, while allowing the timely completion of chemotherapy and therapeutic goals. The decision process is complex and involves consideration of issues related to cancer stage and location, comorbidity, technical surgical issues, treatment needs, and patient desires related to quality of life and lifestyle issues (",
"    <a class=\"graphic graphic_table graphicRef75096 \" href=\"mobipreview.htm?24/60/25547\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    While patient preference is of the utmost importance, there are some absolute and relative contraindications to the use of various bowel segments and continent urinary reservoirs (",
"    <a class=\"graphic graphic_table graphicRef74170 \" href=\"mobipreview.htm?13/53/14171\">",
"     table 6",
"    </a>",
"    ). In addition, patients should be informed that intraoperative findings may dictate a change in the planned form of urinary diversion, such as a foreshortened mesentery, or cancer-related issues, such as a positive urethral margin or gross extravesical disease precluding a negative surgical margin. Even when an orthotopic neobladder is planned, all patients should have a stoma site marked preoperatively by an enterostomal therapist and select either a cutaneous continent diversion or an ileal conduit as an alternative diversion, in case it becomes necessary based upon intraoperative findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Surgical and oncologic considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of cystectomy for bladder cancer is control of the underlying tumor, and every effort must be made to avoid compromising the effectiveness of the resection. Disease extent and anatomic considerations can limit reconstructive options.",
"   </p>",
"   <p>",
"    The incidence of urethral recurrence after radical cystectomy ranges from 0.5 to 18 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/53-55,61,62,74-79\">",
"     53-55,61,62,74-79",
"    </a>",
"    ], and a meta-analysis including more than 3100 patients described an overall risk of 8 percent for urethral recurrence after radical cystectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. Most recurrences are apparent within the first two years following cystectomy, although late recurrences have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/53-55,61,62,74-79,81-83\">",
"     53-55,61,62,74-79,81-83",
"    </a>",
"    ]. Therefore, regular follow-up of the retained urethra is indicated.",
"   </p>",
"   <p>",
"    Several risk factors have been associated with urethral recurrence after radical cystectomy, including multifocal disease, carcinoma in situ (CIS), upper tract urothelial carcinoma, and involvement of the bladder neck or prostatic urethra [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/53-55,61,62,74-79,81-83\">",
"     53-55,61,62,74-79,81-83",
"    </a>",
"    ]. In men, one of the most important risk factors for urethral recurrence is prostatic stromal invasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/84-87\">",
"     84-87",
"    </a>",
"    ]. In a study of 436 radical cystectomy patients, the five-year probability of urethral recurrence was 6 percent for patients without prostatic involvement compared to 15 percent for patients with superficial involvement and 21 percent for those with stromal invasion of the prostate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/55\">",
"     55",
"    </a>",
"    ]. Based upon these observations, an intraoperative frozen section of the distal urethral margin has been recommended before proceeding with an orthotopic neobladder, rather than relying upon preoperative criteria to predict urethral recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In women, bladder neck involvement is thought to be associated with a higher incidence of urethral recurrence and represents an absolute contraindication to an orthotopic diversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/88-90\">",
"     88-90",
"    </a>",
"    ]. Some investigators have proposed using intraoperative frozen section of the urethral margin to determine whether or not an orthotopic reconstruction is possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/80,88\">",
"     80,88",
"    </a>",
"    ]. However, the decision to perform an orthotopic diversion in a female with tumor at the bladder neck should not be taken lightly, since urethral recurrence in a female is equivalent to a pelvic recurrence, which leads to death. Furthermore, some women will have periurethral gland involvement on final pathology despite having negative urethral biopsies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 251 male patients, preoperative urethral biopsy had a 99 percent negative predictive value, and intraoperative urethral margin had a 100 percent negative predictive value for predicting the status of the final urethral margin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/91\">",
"     91",
"    </a>",
"    ]. These data reinforce the recommendation for intraoperative analysis of the urethral margin on frozen tissue for all patients. The prognostic value of final urethral margin status is influenced by the presence of bladder cancer within the prostatic urethra, ducts or stroma in the final pathological specimen.",
"   </p>",
"   <p>",
"    When patients are properly selected for orthotopic diversion, the risk of urothelial recurrence is small, and a close follow-up with prompt intervention for urethral recurrence can result in a good oncologic outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/53-55,61,62,74-79\">",
"     53-55,61,62,74-79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urethral recurrence often presents with bloody urethral discharge,",
"    <span class=\"nowrap\">",
"     pelvic/perineal",
"    </span>",
"    pain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a mass in the urethra [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/53-55,61,62,74-79\">",
"     53-55,61,62,74-79",
"    </a>",
"    ], and can occur up to 20 years after RC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/92\">",
"     92",
"    </a>",
"    ]. The management of urethral recurrence after cystectomy is total urethrectomy, including excision of the meatus. We follow patients with a urine cytology using either a voided or urethral wash specimen depending on the diversion, and we urethroscope any patient with urethral-related symptoms, abnormal discharge, or hematuria. Surgical management of these recurrences has limited morbidity and, when revision of the diversion is indicated, a continent diversion can be maintained [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/53-55,61,62,74-79\">",
"     53-55,61,62,74-79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transurethral management of noninvasive urethral recurrences has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/55,74\">",
"     55,74",
"    </a>",
"    ]. With proper patient selection, this approach may obviate a more invasive urethrectomy and revision of the urinary diversion. Intraurethral therapy with BCG has been described with mixed results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/76,93\">",
"     76,93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40122?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of non-muscle-invasive bladder cancer\", section on 'Intravesical BCG'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with urethral and ureterointestinal anastomotic recurrence and gross disease on cross-sectional imaging should be considered for systemic chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/27/19897?source=see_link\">",
"     \"Treatment of metastatic urothelial cancer of the bladder and urinary tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Creation of an orthotopic neobladder requires that the urethra be free of cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men, intraoperative frozen section assessment of the urethral margin is required, even if the preoperative evaluation was negative. Transurethral prostatic biopsy was initially recommended as a means of assessing prostatic urethral involvement prior to construction of an orthotopic neobladder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/94\">",
"       94",
"      </a>",
"      ]. However, biopsy results do not always correlate with final histology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/85,91\">",
"       85,91",
"      </a>",
"      ]. Furthermore, although microscopic involvement of the prostatic urethra may be predictive of a higher rate of urethral recurrence, lower than expected urethral recurrence rates have been observed in orthotopically reconstructed patients despite involvement of the prostate. Thus, routine preoperative prostatic biopsies are no longer recommended.",
"     </li>",
"     <li>",
"      In women, creation of an orthotopic neobladder is contraindicated when there is overt involvement of the urethra. Tumor involvement of the bladder neck or invasion of the anterior vaginal wall is associated with an increased risk of urethral involvement. However, 50 percent of woman with bladder neck involvement have no pathologic evidence of urethral involvement following cystectomy and urethrectomy. Full thickness frozen section biopsy of the urethral margin has been found to reliably identify urethral involvement and is mandatory at the time of cystectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/56\">",
"       56",
"      </a>",
"      ]. With proper evaluation of the urethra, women appear to be at a similarly low risk of developing urethral recurrence following orthotopic reconstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Locally advanced bladder cancer",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    regional node-positive disease used to be an absolute contraindication for a continent cutaneous or orthotopic urethral diversion for fear of the difficulty in treating a local recurrence or giving chemotherapy and radiation therapy with a urinary reservoir. Generally, an ileal conduit remains the preferred diversion in this situation because of the quicker recovery time and lower risk of perioperative complications.",
"   </p>",
"   <p>",
"    However, continent orthotopic urethral diversions and continent cutaneous diversions have been used successfully in carefully selected patients. One series describes 357 men who underwent cystectomy and the creation of an ileal neobladder, including 36 who had locally advanced bladder cancer and 17 who had distant metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. Of the 43 patients who developed a local recurrence, 40 (93 percent) maintained good neobladder function until death. Local recurrence compromised the upper urinary tract in 24 cases, neobladder in 10, and intestinal tract in seven, but only required the removal of the neobladder in one case because of an enterovesical fistula to the pouch.",
"   </p>",
"   <p>",
"    Although the dwell time of urine in the reservoirs during chemotherapy is a concern related to the potential toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/97\">",
"     97",
"    </a>",
"    ], this issue has generally been managed by the use of an indwelling catheter during the chemotherapy infusion along with increased hydration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data are limited regarding the proportion of patients in whom adjuvant chemotherapy must be delayed because of postoperative complications. Neoadjuvant chemotherapy significantly reduces the risk of death in patients with muscle-invasive bladder cancer, and patients who receive neoadjuvant chemotherapy are more likely to be able to receive their chemotherapy than those treated after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/99\">",
"     99",
"    </a>",
"    ]. Therefore, it is critical to have an honest, informed, and meaningful discussion with patients in a preoperative setting where the risks and benefits of all forms of urinary diversions are discussed in detail. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29766?source=see_link\">",
"     \"Adjuvant chemotherapy for muscle invasive urothelial (transitional cell) carcinoma of the bladder\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/0/41992?source=see_link\">",
"     \"Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urinary diversion with neobladder construction can be considered in selected patients with regional metastases or locally advanced disease, as few such patients will experience complications that disrupt neobladder function. In contrast, a short life expectancy and an inability to perform intermittent catheterization are contraindications to orthotopic reconstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Prior pelvic radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precystectomy pelvic radiation therapy (RT) formerly was thought to impair functional outcomes (particularly continence) and increase postoperative complications (eg, wound infections, ureteroileal anastomotic leaks). These concerns arose from earlier reports of a high incidence of serious complications following salvage cystectomy after failure of primary RT for bladder cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. However, more recent studies support the feasibility of continent urinary diversions in irradiated patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective series of 86 patients undergoing continent cutaneous diversion, 44 of whom were previously irradiated, there were no significant differences between irradiated and nonirradiated patients with respect to operative time, intraoperative blood loss, or transfusion requirements [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/102\">",
"       102",
"      </a>",
"      ]. The irradiated group had eight urine leaks (20 percent) with three requiring surgical repair, while the control group had five urine leaks (12 percent), one requiring repair.",
"     </li>",
"     <li>",
"      In a cohort of 18 patients who underwent cystectomy and urinary reconstruction after pelvic RT, daytime and nighttime continence rates were only 67 and 56 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/103\">",
"       103",
"      </a>",
"      ]. However, for those with persistent postoperative incontinence, placement of an artificial urethral sphincter successfully restored complete voiding control in all patients with incontinence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Diversion after pelvic radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystectomy and urinary diversion is a technically complex and demanding procedure with a high risk for perioperative complications in the best of hands and should not be performed by a urologist who does an occasional cystectomy.",
"   </p>",
"   <p>",
"    For patients who have had prior radiation therapy, careful attention should be paid to the character, viability, and vascularity of the tissues, particularly the ureters and urethra. The bowel segment to be used for diversion may need to be altered based upon intraoperative findings of irradiated bowel segments. Although transverse colon has been historically advocated in this scenario, the ileum can be safely used in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common complications reported in surgical series of previously irradiated patients include ureteral stricture in up to 32 percent, prolonged incontinence in up to 44 percent, stomal problems in up to 39 percent, and fistulas in up to 7 percent. Reoperation is required to address these complications in 8 to 69 percent of patients; the most common reasons for reoperation include stomal revisions, ureteral anastomotic revisions, and procedures to correct incontinence and repair of fistulas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/103,105\">",
"     103,105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Psychosocial and medical considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors need to be considered when choosing the appropriate procedure for an individual patient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In choosing the appropriate procedure, the patient and his or her family should have realistic expectations about the outcome associated with each reconstruction option. They also need to understand the efforts that will be required on their part during the rehabilitation process. In addition, patients need to have sufficient manual dexterity to master self-catheterization if the decision is made to proceed with a continent diversion. In addition to the physician, the enterostomal nurse specialist can be invaluable in educating the patient and family and assisting with the decision-making process [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Advanced age can complicate both the procedure and the rehabilitation process. However, physiologic age is more relevant and no formal cutoff should be applied. Older patients need to be aware that recovery of continence may take longer than in younger patients. Nonetheless, the ultimate results seem to be equivalent similar to those achievable in younger patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/107,108\">",
"       107,108",
"      </a>",
"      ]. Our policy is to offer continent diversions to older patients if they are healthy and motivated enough to care for the diversion. If an older patient subsequently becomes unable to care for the continent diversion, then an indwelling Foley catheter may be placed into the diversion similar to what might be done for the native bladder.",
"     </li>",
"     <li>",
"      Obesity increases the technical difficulty of cystectomy and may complicate orthotopic neobladder construction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/109\">",
"       109",
"      </a>",
"      ]. However, the postoperative management of an ileal loop conduit or a continent reservoir is also more difficult in the obese patient, and most surgeons do not consider obesity to be a contraindication to reconstruction with an orthotopic neobladder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/110\">",
"       110",
"      </a>",
"      ]. Many, including the author, feel that reconstruction to the urethra may be the least complicated reconstructive option for the obese patient. However, obesity may be associated with a higher incidence of a thickened foreshortened mesenteric root, which can preclude the ability to anastomose an orthotopic urinary diversion to the native urethra.",
"     </li>",
"     <li>",
"      Adequate renal function is required for the creation of any continent diversion. Urinary excretion products are resorbed through the mucosal surface, imposing an extra metabolic burden on the kidneys. Typically only mild metabolic abnormalities will be observed in patients who have normal renal function. For those with more severe renal dysfunction with (serum creatinine values &gt;2.0-2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [180-230",
"      <span class=\"nowrap\">",
"       microM/L]),",
"      </span>",
"      an ileal loop conduit is preferred over other approaches.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several complications can be associated with urinary diversion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Surgery-related complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considerable variability exists in the reported early and long-term morbidity rates following urinary diversions. Within the first 30 days after surgery, morbidity rates range between 20 to 56 percent and beyond 30 days from 28 to 94 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/24,111,112\">",
"     24,111,112",
"    </a>",
"    ]. Diversion-related complications are specific to the type of diversion and are generally categorized into those involving the bowel anastomosis, those related to the type of",
"    <span class=\"nowrap\">",
"     reservoir/conduit,",
"    </span>",
"    and those associated with the ureterointestinal anastomosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ileal conduit is often chosen for patients with significant medical comorbidities in an effort to minimize postoperative complications. Because of the higher incidence of preoperative risk factors in patients undergoing ileal conduit diversions, the rate of surgical complications still approaches that of continent diversions performed in healthier patients (",
"    <a class=\"graphic graphic_table graphicRef63297 \" href=\"mobipreview.htm?27/25/28060\">",
"     table 7",
"    </a>",
"    ). None of the comparative studies control for comorbidities, and that complication rates would be even higher in patients with continent diversions and higher comorbidity indexes.",
"   </p>",
"   <p>",
"    The overall rate of complications associated with conduits is similar for ileum and colon segments among properly selected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/24,113,114\">",
"     24,113,114",
"    </a>",
"    ]. The four most common complications reported are pyelonephritis, ureteral obstruction, urinary calculi, and stomal complications (in 5 to 23, 2 to 22, 3 to 16, and 2 to 62 percent of cases, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/24\">",
"     24",
"    </a>",
"    ]. As an example, long-term outcomes were analyzed in a series of 412 patients undergoing ileal conduits at a median follow-up of 98 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/24\">",
"     24",
"    </a>",
"    ]. The frequency of complications increased from 45 percent at five years to 94 percent at greater than 15 years. The most frequent complications were renal insufficiency, stomal problems, bowel problems, urinary tract infections, ureteral obstruction, and urinary calculi (in 27 24, 24, 24, 14, and 9 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Continent urinary diversions involve multiple suture lines, valve mechanisms, tapered limbs, and longer operative times compared to ileal conduits. As such, they are subject to a higher incidence of urinary leaks in the early postoperative period and may be subject to pouch rupture at any time.",
"   </p>",
"   <p>",
"    The complications seen with continent urinary diversions differ in the early postoperative period compared to those seen long term and are specific to the type of reservoir (",
"    <a class=\"graphic graphic_table graphicRef76468 \" href=\"mobipreview.htm?35/44/36556\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/26,32,111,114-116\">",
"     26,32,111,114-116",
"    </a>",
"    ]. If one combines the reported percentage of early and late complications in large institutional series associated with each procedure, the risk of having a significant complication over the lifetime of the patient is about 10 to 8 percent for orthotopic neobladders and 18 to 38 percent for continent cutaneous reservoirs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Urinary continence and/or voiding dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported rates of incontinence for patients with continent cutaneous diversions vary significantly depending upon the criteria used to define incontinence and the differences in the length of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/26,32,111,114-116\">",
"     26,32,111,114-116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Daytime and nighttime continence rates with continent cutaneous reservoirs are reported in the range of 90 to 98 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. The most frequent and troublesome long-term complication associated with continent cutaneous diversions involves the efferent limb and catheterizable stoma. The reported rate of stomal stenosis and difficulty in catheterizing the stoma is 4 to 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/32,116\">",
"     32,116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lack of uniformity in defining voiding dysfunction and incontinence, the often retrospective nature of assessment, and the lack of validated instruments to measure symptoms in orthotopic neobladders series limit our ability to assess voiding dysfunction after neobladder diversions. A recent meta-analysis of more than 2000 patients showed a 4 to 25 percent rate of intermittent self-catheterization for incomplete emptying [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/52\">",
"     52",
"    </a>",
"    ]. Daytime incontinence was present in approximately 13 percent of patients. The rate of nocturnal incontinence is usually higher due to lack of the guarding reflex from loss of the native bladder and is in the range of 15 to 40 percent.",
"   </p>",
"   <p>",
"    Incontinence with a continent cutaneous diversion can be due to uninhibited pouch contractions, poor pouch compliance, or an incompetent continence mechanism. Pouch urodynamics are helpful in categorizing the cause of the incontinence.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with a poorly compliant, high-pressure reservoir, an initial trial of anticholinergics is the preferred approach. Refractory cases usually benefit from augmenting the reservoir with a patch of bowel to decrease pressures and increase capacity.",
"     </li>",
"     <li>",
"      Incompetent continence mechanisms usually require open revision. Minimally invasive approaches such as injecting bulking agents often are helpful for mild incontinence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Diminished renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compromise of renal function over time may be observed in some patients after urinary diversion. The development of urinary tract obstruction (at the site of either ureteral implantation site or",
"    <span class=\"nowrap\">",
"     reservoir/conduit",
"    </span>",
"    outflow), stones, and chronic infection are contributory factors. However, it is not clear whether the loss of renal function exceeds that expected in an aging population, since kidney function gradually deteriorates in the elderly, even in the absence of urinary tract surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/22\">",
"     22",
"    </a>",
"    ]. Careful surveillance for evidence of obstruction or stone formation will allow for prompt intervention and may prevent loss of renal function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link&amp;anchor=H20658511#H20658511\">",
"     \"Assessment of kidney function\", section on 'Change in GFR with aging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious complications can contribute to acute morbidity and chronic renal insufficiency. Among the contributory factors are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intestinal segments, which are used to fashion the",
"      <span class=\"nowrap\">",
"       reservoir/conduit,",
"      </span>",
"      are normally colonized with bacteria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/119\">",
"       119",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Incomplete voluntary voiding may leave residual urine, a nidus for infection",
"     </li>",
"     <li>",
"      Intermittent catheterization may contribute by introducing bacteria into the reservoir in a retrograde manner, especially if it is done carelessly",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the presence of small bowel intestinal mucosa appears to promote asymptomatic bacterial colonization, urosepsis rarely occurs unless the patient has recurrent urinary tract infections. This was illustrated in a series of 66 patients with orthotopic neobladders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/120\">",
"     120",
"    </a>",
"    ]. Asymptomatic bacteriuria was seen in 78 percent of the 55 patients who voided through an orthotopic neobladder, while only 39 percent developed urinary infection, and urosepsis rarely occurred, except in the context of recurrent urinary tract infections. Thus, patients do not require chronic suppressive antibiotic therapy unless there is a history of recurrent infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Nutritional and metabolic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resection of an ileal or colonic segment of bowel may result in malabsorption of bile salts and vitamin B12, while use of any bowel segment for a reservoir or conduit can cause metabolic abnormalities through the resorption of urinary metabolites via the intestinal mucosa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extensive ileal resection can lead to lipid malabsorption and gallstone formation secondary to the loss of bile salts, which are absorbed in the terminal ileum. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/50/41765?source=see_link&amp;anchor=H2#H2\">",
"       \"Mechanisms of nutrient absorption and malabsorption\", section on 'Fat absorption'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      However, the ileal segments used for urinary reconstruction are generally short enough to avoid this problem [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/18\">",
"       18",
"      </a>",
"      ]. In one observational study of 114 individuals without a history of symptomatic gallstone disease or previous cholecystectomy at the time of urinary diversion, 10 percent of men and 25 percent of women developed gallstones, an incidence consistent with that expected in the American population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/121\">",
"       121",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4489?source=see_link&amp;anchor=H14#H14\">",
"       \"Epidemiology of and risk factors for gallstones\", section on 'Gallbladder stasis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If an ileal segment is used for the urinary diversion, there may not be sufficient residual ileal mucosa to facilitate adequate absorption of the vitamin B12 intrinsic factor complex [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/18\">",
"       18",
"      </a>",
"      ]. Clinical vitamin B12 deficiency may ensue, manifested as either a megaloblastic anemia or with neurologic symptoms. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/32/11786?source=see_link&amp;anchor=H3#H3\">",
"       \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\", section on 'Dietary intake and absorption'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The true incidence of B12 deficiency is unclear. Long-term estimates range from zero to as high as 33 percent five years after urinary reconstruction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/95,122\">",
"       95,122",
"      </a>",
"      ]. Some of the variability may be due to the method of screening for B12 deficiency (ie, Schilling test, serum B12 levels, methylmalonic acid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      homocysteine levels, or overt megaloblastic anemia), as well as differences related to the length and section of ileum used for the urinary diversion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/123,124\">",
"       123,124",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Periodic monitoring of B12 levels should be considered in all patients who undergo urinary diversion using the terminal ileum, particularly long-term survivors. The author recommends that B12 levels be monitored annually beginning three to five years following diversion and that patients be evaluated for symptoms consistent with B12 deficiency. Replacement therapy should be initiated as needed.",
"     </li>",
"     <li>",
"      Hyperchloremic metabolic acidosis can result from resorption of excreted metabolites through the intestinal mucosa. Although severe acidosis is a major problem following ureterosigmoidostomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/18\">",
"       18",
"      </a>",
"      ], it is less frequent with newer reconstructive procedures that limit the amount of time that urine is in contact with bowel mucosa. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29589?source=see_link&amp;anchor=H7#H7\">",
"       \"Acid-base and electrolyte abnormalities with diarrhea or ureteral diversion\", section on 'Ureteral diversion'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      As an example, in one series of 363 men with ileal neobladders, only 1 percent developed severe metabolic acidosis, although nearly one-half required some form of alkalinizing treatment due to mild acidosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/95\">",
"       95",
"      </a>",
"      ]. Regardless of the type of diversion, regular monitoring of electrolytes with each follow-up visit will allow for the institution of appropriate corrective therapy as needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less common complications associated with urinary diversions include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All urinary diversions using bowel, with or without separation of urine and feces, may carry a higher risk for intestinal tumor development compared to the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/125\">",
"       125",
"      </a>",
"      ]. This mixing causes progressive changes including relatively thin intestinal epithelium with villous atrophy which initially does not have dysplastic or neoplastic features [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/126\">",
"       126",
"      </a>",
"      ]. The mixing of fecal and urinary streams with a standard ureterosigmoidostomy or its variants results in an increased risk of the development of adenocarcinoma with a median latency of 26 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/127\">",
"       127",
"      </a>",
"      ]. The pathogenesis of such tumors remains uncertain, but it may be a consequence of a combination of carcinogenic action and mucosal cellular instability at the anastomotic site leading first to dysplasia and subsequently to carcinoma. Patients undergoing ureterosigmoidostomy should be given information concerning this risk and should undergo regular colonoscopic surveillance beginning five years after surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/128,129\">",
"       128,129",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Although the frequency of malignancy is higher following ureterosigmoidostomy compared to an ileal conduit or continent diversion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/130,131\">",
"       130,131",
"      </a>",
"      ], long-term follow-up of large cohorts will be needed to estimate the incidence of such cancers with newer conduits and reservoirs. Appropriate evaluation of symptomatic patients is required to evaluate for disease recurrence or the development of new tumors.",
"     </li>",
"     <li>",
"      Spontaneous rupture of either a continent cutaneous reservoir or an orthotopic neobladder is rare [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/132\">",
"       132",
"      </a>",
"      ]. Generally this has been associated with either acute or chronic neobladder overdistention. Generally this has been associated with poor compliance with catheterization of a continent cutaneous reservoir or, rarely, with acute or chronic neobladder overdistention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/54/15205?source=see_link\">",
"       \"Patient information: Bladder cancer treatment; invasive cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continent reservoirs from detubularized loops of intestine have become the procedure of choice for urinary diversion in both men and women undergoing radical cystectomy. In appropriately selected patients, the creation of an orthotopic neobladder permits the elimination of an external stoma and the preservation of body image without compromising cancer surgery. The patient needs to fully educated about the necessary commitment to the rehabilitation process, and needs to possess adequate manual dexterity to perform self-catheterization, if that becomes necessary.",
"   </p>",
"   <p>",
"    When involvement of the urinary outflow tract by tumor prevents the use of an orthotopic neobladder, a continent cutaneous reservoir may still offer substantial advantages over an incontinent ileal conduit. For patients who are not candidates for either type of continent diversion, the ileal loop remains an acceptable and reliable alternative.",
"   </p>",
"   <p>",
"    With these advances in reconstructive surgery, patients may accept radical cystectomy earlier in the natural history of bladder cancer, rather than reserving cystectomy as a second-line procedure. This may ultimately improve the outcome of bladder cancer treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/34/32298/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/1\">",
"      Estape R, Mendez LE, Angioli R, Penalver M. Urinary diversion in gynecologic oncology. Surg Clin North Am 2001; 81:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/2\">",
"      Petros JG, Augustinos P, Lopez MJ. Pelvic exenteration for carcinoma of the colon and rectum. Semin Surg Oncol 1999; 17:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/3\">",
"      Kaefer M, Tobin MS, Hendren WH, et al. Continent urinary diversion: the Children's Hospital experience. J Urol 1997; 157:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/4\">",
"      Adams MC, Mitchell ME, Rink RC. Gastrocystoplasty: an alternative solution to the problem of urological reconstruction in the severely compromised patient. J Urol 1988; 140:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/5\">",
"      Kaveggia FF, Thompson JS, Schafer EC, et al. Hyperammonemic encephalopathy in urinary diversion with urea-splitting urinary tract infection. Arch Intern Med 1990; 150:2389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/6\">",
"      McDougal WS, Koch MO. Accurate determination of renal function in patients with intestinal urinary diversions. J Urol 1986; 135:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/7\">",
"      Koch MO, McDougal WS, Flora MD. Urease and the acidosis of urinary intestinal diversion. J Urol 1991; 146:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/8\">",
"      Koch MO, McDougal WS, Thompson CO. Mechanisms of solute transport following urinary diversion through intestinal segments: an experimental study with rats. J Urol 1991; 146:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/9\">",
"      Klein EA, Montie JE, Montague DK, et al. Jejunal conduit urinary diversion. J Urol 1986; 135:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/10\">",
"      Plawker MW, Rabinowitz SS, Etwaru DJ, Glassberg KI. Hypergastrinemia, dysuria-hematuria and metabolic alkalosis: complications associated with gastrocystoplasty. J Urol 1995; 154:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/11\">",
"      Nguyen DH, Bain MA, Salmonson KL, et al. The syndrome of dysuria and hematuria in pediatric urinary reconstruction with stomach. J Urol 1993; 150:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/12\">",
"      Gosalbez R Jr, Woodard JR, Broecker BH, Warshaw B. Metabolic complications of the use of stomach for urinary reconstruction. J Urol 1993; 150:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/13\">",
"      Filipsson S, Hult&eacute;n L, Lindstedt G. Malabsorption of fat and vitamin B12 before and after intestinal resection for Crohn's disease. Scand J Gastroenterol 1978; 13:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/14\">",
"      Thompson WG, Wrathell E. The relation between ileal resection and vitamin B12 absorption. Can J Surg 1977; 20:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/15\">",
"      Koch MO, McDougal WS. Chlorpromazine: adjuvant therapy for the metabolic derangements created by urinary diversion through intestinal segments. J Urol 1985; 134:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/16\">",
"      Boyd SD, Schiff WM, Skinner DG, et al. Prospective study of metabolic abnormalities in patient with continent Kock pouch urinary diversion. Urology 1989; 33:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/17\">",
"      Koch MO, Gurevitch E, Hill DE, McDougal WS. Urinary solute transport by intestinal segments: a comparative study of ileum and colon in rats. J Urol 1990; 143:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/18\">",
"      Mills RD, Studer UE. Metabolic consequences of continent urinary diversion. J Urol 1999; 161:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/19\">",
"      Stampfer DS, McDougal WS, McGovern FJ. The use of in bowel urology. Metabolic and nutritional complications. Urol Clin North Am 1997; 24:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/20\">",
"      McDougal WS, Stampfer DS, Kirley S, et al. Intestinal ammonium transport by ammonium and hydrogen exchange. J Am Coll Surg 1995; 181:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/21\">",
"      BRICKER EM. Bladder substitution after pelvic evisceration. Surg Clin North Am 1950; 30:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/22\">",
"      Hautmann RE. Urinary diversion: ileal conduit to neobladder. J Urol 2003; 169:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/23\">",
"      Gschwend JE. Bladder substitution. Curr Opin Urol 2003; 13:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/24\">",
"      Madersbacher S, Schmidt J, Eberle JM, et al. Long-term outcome of ileal conduit diversion. J Urol 2003; 169:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/25\">",
"      TURNBULL RB Jr. Intestinal stomas. Surg Clin North Am 1958; 38:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/26\">",
"      Farnham SB, Cookson MS. Surgical complications of urinary diversion. World J Urol 2004; 22:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/27\">",
"      Kouba E, Sands M, Lentz A, et al. Incidence and risk factors of stomal complications in patients undergoing cystectomy with ileal conduit urinary diversion for bladder cancer. J Urol 2007; 178:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/28\">",
"      Samuel JD, Bhatt RI, Montague RJ, et al. The natural history of postoperative renal function in patients undergoing ileal conduit diversion for cancer measured using serial isotopic glomerular filtration rate and 99m technetium-mercaptoacetyltriglycine renography. J Urol 2006; 176:2518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/29\">",
"      Bloch WE, Bejany DE, Penalver MA, Politano VA. Complications of the Miami pouch. J Urol 1992; 147:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/30\">",
"      Kock NG, Nilson AE, Nilsson LO, et al. Urinary diversion via a continent ileal reservoir: clinical results in 12 patients. J Urol 1982; 128:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/31\">",
"      Rowland RG, Mitchell ME, Bihrle R, et al. Indiana continent urinary reservoir. J Urol 1987; 137:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/32\">",
"      Holmes DG, Thrasher JB, Park GY, et al. Long-term complications related to the modified Indiana pouch. Urology 2002; 60:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/33\">",
"      Bochner BH, McCreath WA, Aubey JJ, et al. Use of an ureteroileocecal appendicostomy urinary reservoir in patients with recurrent pelvic malignancies treated with radiation. Gynecol Oncol 2004; 94:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/34\">",
"      Mirhashemi R, Lamrbou N, Hus N, et al. The gastrointestinal complications of the Miami Pouch: a review of 77 cases. Gynecol Oncol 2004; 92:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/35\">",
"      Angioli R, Estape R, Cantuaria G, et al. Urinary complications of Miami pouch: trend of conservative management. Am J Obstet Gynecol 1998; 179:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/36\">",
"      Stenzl A, H&ouml;ltl L. Orthotopic bladder reconstruction in women--what we have learned over the last decade. Crit Rev Oncol Hematol 2003; 47:147.",
"     </a>",
"    </li>",
"    <li>",
"     Steven, K, Poulsen, AL. The orthotopic Kock ileal neobladder: functional results, urodynamic features, complications and survival in 166 men. J Urol 200; 164:288.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/38\">",
"      Sullivan JW, Grabstald H, Whitmore WF Jr. Complications of ureteroileal conduit with radical cystectomy: review of 336 cases. J Urol 1980; 124:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/39\">",
"      Middleton AW Jr, Hendren WH. Ileal conduits in children at the Massachusetts General Hospital from 1955 to 1970. J Urol 1976; 115:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/40\">",
"      Richie JP, Skinner DG, Waisman J. The effect of reflux on the development of pyelonephritis in urinary diversion: an experimental study. J Surg Res 1974; 16:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/41\">",
"      Studer UE, Danuser H, Thalmann GN, et al. Antireflux nipples or afferent tubular segments in 70 patients with ileal low pressure bladder substitutes: long-term results of a prospective randomized trial. J Urol 1996; 156:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/42\">",
"      Boxer RJ, Fritzsche P, Skinner DG, et al. Replacement of the ureter by small intestine: clinical application and results of the ileal ureter in 89 patients. J Urol 1979; 121:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/43\">",
"      Pantuck AJ, Han KR, Perrotti M, et al. Ureteroenteric anastomosis in continent urinary diversion: long-term results and complications of direct versus nonrefluxing techniques. J Urol 2000; 163:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/44\">",
"      Shaaban AA, Abdel-Latif M, Mosbah A, et al. A randomized study comparing an antireflux system with a direct ureteric anastomosis in patients with orthotopic ileal neobladders. BJU Int 2006; 97:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/45\">",
"      Madersbacher S, M&ouml;hrle K, Burkhard F, Studer UE. Long-term voiding pattern of patients with ileal orthotopic bladder substitutes. J Urol 2002; 167:2052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/46\">",
"      Simon J, Bartsch G Jr, K&uuml;fer R, et al. Neobladder emptying failure in males: incidence, etiology and therapeutic options. J Urol 2006; 176:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/47\">",
"      Ali-el-Dein B, el-Sobky E, Hohenfellner M, Ghoneim MA. Orthotopic bladder substitution in women: functional evaluation. J Urol 1999; 161:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/48\">",
"      Stenzl A, Jarolim L, Coloby P, et al. Urethra-sparing cystectomy and orthotopic urinary diversion in women with malignant pelvic tumors. Cancer 2001; 92:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/49\">",
"      Hautmann RE, de Petriconi R, Kleinschmidt K, et al. Orthotopic ileal neobladder in females: impact of the urethral resection line on functional results. Int Urogynecol J Pelvic Floor Dysfunct 2000; 11:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/50\">",
"      Arai Y, Okubo K, Konami T, et al. Voiding function of orthotopic ileal neobladder in women. Urology 1999; 54:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/51\">",
"      Stein JP, Penson DF, Lee C, et al. Long-term oncological outcomes in women undergoing radical cystectomy and orthotopic diversion for bladder cancer. J Urol 2009; 181:2052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/52\">",
"      Steers WD. Voiding dysfunction in the orthotopic neobladder. World J Urol 2000; 18:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/53\">",
"      Hassan JM, Cookson MS, Smith JA Jr, Chang SS. Urethral recurrence in patients following orthotopic urinary diversion. J Urol 2004; 172:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/54\">",
"      Stein JP, Clark P, Miranda G, et al. Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients. J Urol 2005; 173:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/55\">",
"      Freeman JA, Tarter TA, Esrig D, et al. Urethral recurrence in patients with orthotopic ileal neobladders. J Urol 1996; 156:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/56\">",
"      Ali-el-Dein B, Abdel-Latif M, Ashamallah A, et al. Local urethral recurrence after radical cystectomy and orthotopic bladder substitution in women: a prospective study. J Urol 2004; 171:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/57\">",
"      Akkad T, Gozzi C, Deibl M, et al. Tumor recurrence in the remnant urothelium of females undergoing radical cystectomy for transitional cell carcinoma of the bladder: long-term results from a single center. J Urol 2006; 175:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/58\">",
"      Bochner BH, Montie JE, Lee CT. Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer. Urol Clin North Am 2003; 30:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/59\">",
"      Knapik JA, Murphy WM. Urethral wash cytopathology for monitoring patients after cystoprostatectomy with urinary diversion. Cancer 2003; 99:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/60\">",
"      Lin DW, Herr HW, Dalbagni G. Value of urethral wash cytology in the retained male urethra after radical cystoprostatectomy. J Urol 2003; 169:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/61\">",
"      Taylor JM, Spiess PE, Kassouf W, et al. Management of urethral recurrence after orthotopic urinary diversion. BJU Int 2010; 106:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/62\">",
"      Clark PE, Stein JP, Groshen SG, et al. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. J Urol 2004; 172:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/63\">",
"      Dutta SC, Chang SC, Coffey CS, et al. Health related quality of life assessment after radical cystectomy: comparison of ileal conduit with continent orthotopic neobladder. J Urol 2002; 168:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/64\">",
"      Hobisch A, Tosun K, Kinzl J, et al. Quality of life after cystectomy and orthotopic neobladder versus ileal conduit urinary diversion. World J Urol 2000; 18:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/65\">",
"      Smith JA. The quality of life in men after radical cystectomy with a continent cutaneous diversion or orthotopic bladder substitution: is there a difference? J Urol 2003; 170:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/66\">",
"      M&aring;nsson A, Davidsson T, Hunt S, M&aring;nsson W. The quality of life in men after radical cystectomy with a continent cutaneous diversion or orthotopic bladder substitution: is there a difference? BJU Int 2002; 90:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/67\">",
"      Henningsohn L, Steven K, Kallestrup EB, Steineck G. Distressful symptoms and well-being after radical cystectomy and orthotopic bladder substitution compared with a matched control population. J Urol 2002; 168:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/68\">",
"      Porter MP, Penson DF. Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol 2005; 173:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/69\">",
"      Link RE, Lerner SP. Rebuilding the lower urinary tract after cystectomy: a roadmap for patient selection and counseling. Semin Urol Oncol 2001; 19:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/70\">",
"      Austin PF, DeLeary G, Homsy YL, et al. Long-term metabolic advantages of a gastrointestinal composite urinary reservoir. J Urol 1997; 158:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/71\">",
"      Lockhart JL, Davies R, Cox C, et al. The gastroileoileal pouch: an alternative continent urinary reservoir for patients with short bowel, acidosis and/or extensive pelvic radiation. J Urol 1993; 150:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/72\">",
"      Ravi R, Dewan AK, Pandey KK. Transverse colon conduit urinary diversion in patients treated with very high dose pelvic irradiation. Br J Urol 1994; 73:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/73\">",
"      Kato H, Igawa Y, Komiyama I, Nishizawa O. Continent urinary reservoir formation with transverse colon for patients with pelvic irradiation. Int J Urol 2002; 9:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/74\">",
"      Yossepowitch O, Dalbagni G, Golijanin D, et al. Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence. J Urol 2003; 169:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/75\">",
"      Huguet J, Palou J, Serrallach M, et al. Management of urethral recurrence in patients with Studer ileal neobladder. Eur Urol 2003; 43:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/76\">",
"      Varol C, Thalmann GN, Burkhard FC, Studer UE. Treatment of urethral recurrence following radical cystectomy and ileal bladder substitution. J Urol 2004; 172:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/77\">",
"      Nieder AM, Sved PD, Gomez P, et al. Urethral recurrence after cystoprostatectomy: implications for urinary diversion and monitoring. Urology 2004; 64:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/78\">",
"      Yoshida K, Nishiyama H, Kinoshita H, et al. Surgical treatment for urethral recurrence after ileal neobladder reconstruction in patients with bladder cancer. BJU Int 2006; 98:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/79\">",
"      Freeman JA, Esrig D, Stein JP, Skinner DG. Management of the patient with bladder cancer. Urethral recurrence. Urol Clin North Am 1994; 21:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/80\">",
"      Stenzl A, Bartsch G, Rogatsch H. The remnant urothelium after reconstructive bladder surgery. Eur Urol 2002; 41:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/81\">",
"      Levinson AK, Johnson DE, Wishnow KI. Indications for urethrectomy in an era of continent urinary diversion. J Urol 1990; 144:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/82\">",
"      Tobisu K, Tanaka Y, Mizutani T, Kakizoe T. Transitional cell carcinoma of the urethra in men following cystectomy for bladder cancer: multivariate analysis for risk factors. J Urol 1991; 146:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/83\">",
"      Schellhammer PF, Whitmore WF Jr. Transitional cell carcinoma of the urethra in men having cystectomy for bladder cancer. J Urol 1976; 115:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/84\">",
"      Herr HW, Donat SM, Bajorin DF. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 2001; 165:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/85\">",
"      Donat SM, Wei DC, McGuire MS, Herr HW. The efficacy of transurethral biopsy for predicting the long-term clinical impact of prostatic invasive bladder cancer. J Urol 2001; 165:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/86\">",
"      Lebret T, Herv&eacute; JM, Barr&eacute; P, et al. Urethral recurrence of transitional cell carcinoma of the bladder. Predictive value of preoperative latero-montanal biopsies and urethral frozen sections during prostatocystectomy. Eur Urol 1998; 33:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/87\">",
"      Donat SM, Genega EM, Herr HW, Reuter VE. Mechanisms of prostatic stromal invasion in patients with bladder cancer: clinical significance. J Urol 2001; 165:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/88\">",
"      Stein JP, Esrig D, Freeman JA, et al. Prospective pathologic analysis of female cystectomy specimens: risk factors for orthotopic diversion in women. Urology 1998; 51:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/89\">",
"      Stenzl A, Colleselli K, Poisel S, et al. Anterior exenteration with subsequent ureteroileal urethrostomy in females. Anatomy, risk of urethral recurrence, surgical technique, and results. Eur Urol 1998; 33 Suppl 4:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/90\">",
"      Maralani S, Wood DP Jr, Grignon D, et al. Incidence of urethral involvement in female bladder cancer: an anatomic pathologic study. Urology 1997; 50:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/91\">",
"      Kassouf W, Spiess PE, Brown GA, et al. Prostatic urethral biopsy has limited usefulness in counseling patients regarding final urethral margin status during orthotopic neobladder reconstruction. J Urol 2008; 180:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/92\">",
"      Van Poppel H, Sorgeloose T. Radical cystectomy with or without urethrectomy? Crit Rev Oncol Hematol 2003; 47:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/93\">",
"      Studer UE, Burkhard FC, Schumacher M, et al. Twenty years experience with an ileal orthotopic low pressure bladder substitute--lessons to be learned. J Urol 2006; 176:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/94\">",
"      Hardeman SW, Soloway MS. Urethral recurrence following radical cystectomy. J Urol 1990; 144:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/95\">",
"      Hautmann RE, de Petriconi R, Gottfried HW, et al. The ileal neobladder: complications and functional results in 363 patients after 11 years of followup. J Urol 1999; 161:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/96\">",
"      Hautmann RE, Simon J. Ileal neobladder and local recurrence of bladder cancer: patterns of failure and impact on function in men. J Urol 1999; 162:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/97\">",
"      Srinivas S, Mahalati K, Freiha FS. Methotrexate tolerance in patients with ileal conduits and continent diversions. Cancer 1998; 82:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/98\">",
"      Bulbul MA, Wazzan W, Farhat W, et al. Feasibility of radiation and chemotherapy following cystectomy and orthotopic neobladder for invasive bladder cancer. Can J Urol 1998; 5:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/99\">",
"      Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 2001; 19:4005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/100\">",
"      Smith JA Jr, Whitmore WF Jr. Salvage cystectomy for bladder cancer after failure of definitive irradiation. J Urol 1981; 125:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/101\">",
"      Swanson DA, von Eschenbach AC, Bracken RB, Johnson DE. Salvage cystectomy for bladder carcinoma. Cancer 1981; 47:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/102\">",
"      Ahlering TE, Kanellos A, Boyd SD, et al. A comparative study of perioperative complications with Kock pouch urinary diversion in highly irradiated versus nonirradiated patients. J Urol 1988; 139:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/103\">",
"      Bochner BH, Figueroa AJ, Skinner EC, et al. Salvage radical cystoprostatectomy and orthotopic urinary diversion following radiation failure. J Urol 1998; 160:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/104\">",
"      Chang SS, Alberts GL, Smith JA Jr, Cookson MS. Ileal conduit urinary diversion in patients with previous history of abdominal/pelvic irradiation. World J Urol 2004; 22:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/105\">",
"      Gheiler EL, Wood DP Jr, Montie JE, Pontes JE. Orthotopic urinary diversion is a viable option in patients undergoing salvage cystoprostatectomy for recurrent prostate cancer after definitive radiation therapy. Urology 1997; 50:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/106\">",
"      van Savage JG, Slaughenhoupt BL. Approach to urinary diversion in the surgical patient. J Surg Oncol 2000; 73:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/107\">",
"      Sogni F, Brausi M, Frea B, et al. Morbidity and quality of life in elderly patients receiving ileal conduit or orthotopic neobladder after radical cystectomy for invasive bladder cancer. Urology 2008; 71:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/108\">",
"      Clark PE, Stein JP, Groshen SG, et al. Radical cystectomy in the elderly: comparison of clincal outcomes between younger and older patients. Cancer 2005; 104:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/109\">",
"      Lee CT, Dunn RL, Chen BT, et al. Impact of body mass index on radical cystectomy. J Urol 2004; 172:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/110\">",
"      Reyes MA, Nieder AM, Kava BR, et al. Does body mass index affect outcome after reconstruction of orthotopic neobladder? Urology 2007; 69:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/111\">",
"      Killeen KP, Libertino JA. Management of bowel and urinary tract complications after urinary diversion. Urol Clin North Am 1988; 15:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/112\">",
"      Perimenis P, Burkhard FC, Kessler TM, et al. Ileal orthotopic bladder substitute combined with an afferent tubular segment: long-term upper urinary tract changes and voiding pattern. Eur Urol 2004; 46:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/113\">",
"      Morales P, Golimbu M. Colonic urinary diversion: 10 years of experience. J Urol 1975; 113:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/114\">",
"      Jahnson S, Pedersen J. Cystectomy and urinary diversion during twenty years--complications and metabolic implications. Eur Urol 1993; 24:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/115\">",
"      Parekh DJ, Gilbert WB, Koch MO, Smith JA Jr. Continent urinary reconstruction versus ileal conduit: a contemporary single-institution comparison of perioperative morbidity and mortality. Urology 2000; 55:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/116\">",
"      Webster C, Bukkapatnam R, Seigne JD, et al. Continent colonic urinary reservoir (Florida pouch): long-term surgical complications (greater than 11 years). J Urol 2003; 169:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/117\">",
"      Sumfest JM, Burns MW, Mitchell ME. The Mitrofanoff principle in urinary reconstruction. J Urol 1993; 150:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/118\">",
"      Bihrle R. The Indiana pouch continent urinary reservoir. Urol Clin North Am 1997; 24:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/119\">",
"      Wullt B, Holst E, Steven K, et al. Microbial flora in ileal and colonic neobladders. Eur Urol 2004; 45:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/120\">",
"      Wood DP Jr, Bianco FJ Jr, Pontes JE, et al. Incidence and significance of positive urine cultures in patients with an orthotopic neobladder. J Urol 2003; 169:2196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/121\">",
"      Holmes DG, Park GY, Thrasher JB, et al. Incidence of cholelithiasis in 125 continent urinary diversions. J Urol 2001; 165:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/122\">",
"      Steven K, Poulsen AL. The orthotopic Kock ileal neobladder: functional results, urodynamic features, complications and survival in 166 men. J Urol 2000; 164:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/123\">",
"      Fujisawa M, Gotoh A, Nakamura I, et al. Long-term assessment of serum vitamin B(12) concentrations in patients with various types of orthotopic intestinal neobladder. Urology 2000; 56:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/124\">",
"      Ganesan T, Khadra MH, Wallis J, Neal DE. Vitamin B12 malabsorption following bladder reconstruction or diversion with bowel segments. ANZ J Surg 2002; 72:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/125\">",
"      North AC, Lakshmanan Y. Malignancy associated with the use of intestinal segments in the urinary tract. Urol Oncol 2007; 25:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/126\">",
"      Aragona F, De Caro R, Parenti A, et al. Structural and ultrastructural changes in ileal neobladder mucosa: a 7-year follow-up. Br J Urol 1998; 81:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/127\">",
"      Pickard R. Tumour formation within intestinal segments transposed to the urinary tract. World J Urol 2004; 22:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/128\">",
"      Azimuddin K, Khubchandani IT, Stasik JJ, et al. Neoplasia after ureterosigmoidostomy. Dis Colon Rectum 1999; 42:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/129\">",
"      Fichtner J. Follow-up after urinary diversion. Urol Int 1999; 63:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/130\">",
"      Austen M, K&auml;lble T. Secondary malignancies in different forms of urinary diversion using isolated gut. J Urol 2004; 172:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/131\">",
"      Ali-El-Dein B, El-Tabey N, Abdel-Latif M, et al. Late uro-ileal cancer after incorporation of ileum into the urinary tract. J Urol 2002; 167:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/34/32298/abstract/132\">",
"      Desgrandchamps F, Cariou G, Barthelemy Y, et al. Spontaneous rupture of orthotopic detubularized ileal bladder replacement: report of 5 cases. J Urol 1997; 158:798.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2958 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-41.78.124.10-207A0925F2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_34_32298=[""].join("\n");
var outline_f31_34_32298=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ILEAL CONDUITS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Long-term outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CONTINENT CUTANEOUS DIVERSIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ORTHOTOPIC NEOBLADDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Role of anti-reflux anastomosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Functional outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Oncologic outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Men",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      FACTORS INFLUENCING CHOICE OF PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Surgical and oncologic considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Prior pelvic radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Diversion after pelvic radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Psychosocial and medical considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Surgery-related complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Urinary continence and/or voiding dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Diminished renal function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Nutritional and metabolic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/2958\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/2958|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/60/30669\" title=\"table 1\">",
"      Metab conseq bowel segment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/60/7115\" title=\"table 2\">",
"      Ideal char urin reservoir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/34/3629\" title=\"table 3\">",
"      Func out men rad cystect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/5/39003\" title=\"table 4\">",
"      Func out women rad cystect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/60/25547\" title=\"table 5\">",
"      Issues urin div selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/53/14171\" title=\"table 6\">",
"      Contraindication neobladder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/25/28060\" title=\"table 7\">",
"      Diversions vs conduits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/44/36556\" title=\"table 8\">",
"      Early vs late diver comps",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/57/29589?source=related_link\">",
"      Acid-base and electrolyte abnormalities with diarrhea or ureteral diversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/4/29766?source=related_link\">",
"      Adjuvant chemotherapy for muscle invasive urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/24/4489?source=related_link\">",
"      Epidemiology of and risk factors for gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/50/41765?source=related_link\">",
"      Mechanisms of nutrient absorption and malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/0/41992?source=related_link\">",
"      Neoadjuvant treatment and bladder preservation options for muscle-invasive urothelial (transitional cell) bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40802?source=related_link\">",
"      Pathogenesis and clinical manifestations of struvite stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/54/15205?source=related_link\">",
"      Patient information: Bladder cancer treatment; invasive cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/39/634?source=related_link\">",
"      Radical cystectomy and bladder-sparing treatments for urothelial (transitional cell) bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/27/19897?source=related_link\">",
"      Treatment of metastatic urothelial cancer of the bladder and urinary tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40122?source=related_link\">",
"      Treatment of non-muscle-invasive bladder cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_34_32299="DSM-IV-TR diagnostic criteria for cannabis dependence";
var content_f31_34_32299=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F64590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F64590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV-TR diagnostic criteria for cannabis dependence",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       A maladaptive pattern of cannabis use resulting in clinically significant impairment or distress, as indicated by three or more of the following at any time during the same 12 month period:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       1. Tolerance, defined by either of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       a. Using markedly increased amounts of cannabis to achieve the desired effect or intoxication.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       b. Markedly diminished effect with continued use of the same amount of cannabis.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2. Cannabis is often taken in larger amounts or over a longer period than was intended.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3. There is a persistent desire or there are unsuccessful efforts to cut down or control cannabis use.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4. A great deal of time is spent obtaining cannabis, using it, or recovering from its effects.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5. Important social, occupational, or recreational activities are neglected because of cannabis use.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6. Persistent cannabis use despite knowledge of having a recurrent or ongoing physical or psychological problem that is probably caused or exacerbated by cannabis, such as a chronic cough related to smoking or a decrease in goal related activities.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: the Diagnostic and Statistical Manual of Mental Disorders, Text Revision, Fourth Edition (Copyright 2000). American Psychiatric Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_34_32299=[""].join("\n");
var outline_f31_34_32299=null;
var title_f31_34_32300="Guidelines for family and couple therapy";
var content_f31_34_32300=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F78200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F78200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    A practical guide for family and couples therapy for depression",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Principles and tasks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meet with the family",
"       </td>",
"       <td>",
"        Include as many family members as can come and are interested in helping.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elicit everyone's view",
"       </td>",
"       <td>",
"        All family members should discuss their perception of the family's problems, whether related to the depression or not.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assess couples/family functioning",
"       </td>",
"       <td>",
"        Evaluate how the family communicates, solves problems, connects emotionally with each other, assigns family responsibilities, and sets family rules.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Focus on strengths",
"       </td>",
"       <td>",
"        Identify and reinforce family strengths.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluate motivation for change",
"       </td>",
"       <td>",
"        Ensure that families are committed to working together on their problems.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assess safety",
"       </td>",
"       <td>",
"        Ensure that the depressed patient is not suicidal and that there is no family violence.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychoeducation",
"       </td>",
"       <td>",
"        Teach families about depression, including signs and symptoms, etiology, course of illness, and available treatments.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prioritize problems",
"       </td>",
"       <td>",
"        Determine with the family which of their problems they want to address. Prioritize problems related to safety.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Negotiate expectations",
"       </td>",
"       <td>",
"        Establish clinician's expectations for the treatment process, eg, compliance with meetings and working on assigned tasks. Family members should negotiate expected changes with each other.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Set realistic expectations",
"       </td>",
"       <td>",
"        Expectations about change and outcome should be realistic and achievable.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Focus on behaviors and not feelings",
"       </td>",
"       <td>",
"        Feelings cannot be changed and are difficult to measure. Behaviors are more amenable to change and can be evaluated more objectively.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Include some general goals",
"       </td>",
"       <td>",
"        Communicate directly and clearly, support and fulfill appropriate roles as spouse and parent, and reduce criticism, blame, and hostility.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Support increased level of activity",
"       </td>",
"       <td>",
"        The depressed patient should gradually increase participation in activities first within the home and then outside of the home, including greater levels of physical activity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide feedback",
"       </td>",
"       <td>",
"        Inform the family when they are doing well and point out difficulties they are experiencing in making changes.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_34_32300=[""].join("\n");
var outline_f31_34_32300=null;
var title_f31_34_32301="Perinatal complications of maternal diabetic nephropathy";
var content_f31_34_32301=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perinatal complications in infants born to mothers with diabetic nephropathy (2001 to 2012)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Ekbom P, Damm P, Feldt-Rasmussen B, et al. Pregnancy outcome in type 1 diabetic women with microalbuminuria. Diabetes Care 2001; 24:1739.",
"      </li>",
"      <li>",
"       Young EC, Pires ML, Marques LP, et al. Effects of pregnancy on the onset and progression of diabetic nephropathy and of diabetic nephropathy on pregnancy outcomes. Diabetes Metab Syndr 2011; 5:137.",
"      </li>",
"      <li>",
"       Carr DB, Koontz GL, Gardella C, et al. Diabetic nephropathy in pregnancy: suboptimal hypertensive control associated with preterm delivery. Am J Hypertens 2006; 19:513.",
"      </li>",
"      <li>",
"       Yogev Y, Chen R, Ben-Haroush A, et al. Maternal overweight and pregnancy outcome in women with Type-1 diabetes mellitus and different degrees of nephropathy. J Matern Fetal Neonatal Med 2010; 23:999.",
"      </li>",
"      <li>",
"       Nielsen LR, Damm P, Mathiesen ER. Improved pregnancy outcome in type 1 diabetic women with microalbuminuria or diabetic nephropathy: effect of intensified antihypertensive therapy? Diabetes Care 2009; 32:38.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_34_32301=[""].join("\n");
var outline_f31_34_32301=null;
var title_f31_34_32302="Occluding exostosis of the external auditory canal";
var content_f31_34_32302=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Occluding exostosis of the external auditory canal",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Surgical intervention with removal of the exostosis is performed when the exostoses become so large that they occlude the canal, and infections begin to develop because of retained skin and cerumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from Nikolas H Blevins, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_34_32302=[""].join("\n");
var outline_f31_34_32302=null;
var title_f31_34_32303="Pericardial cyst PA";
var content_f31_34_32303=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pericardial cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 293px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAElAV0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5Uooru/hB4QsvGevX9jqDXKpBZ/aEMEqxHd58UfJZGGAJGOMDJAGRQBwlFfTMnwB8OByEv9ZIBxkyxD/2nWlpn7OvhS6UiTUdcEg7LNFj/wBFUAfKlFfWkv7NXhdCcX+vH/ttF/8AGqhb9m7wzwF1DXCSf+e0X/xugD5Ror6yb9m3wqi4bUdeaQ/wpLF/8apD+zV4bCGSXUNZgj9ZLiH+XlUAfJ1FfVI/Z/8ABCuF/tLxFN6sksKD8MxHNadr+zZ4JuVBXVPEIPoZ4f8A41QB8h0V9iH9mHwb21PxD/3/AIf/AI1Sf8Mw+DT/AMxPxCP+28P/AMaoA+PKK+vv+GYfCoc/8TTXCnbE0WT/AOQqJf2ZvBsSbpNU8QA+nnw8n/v1QB8g0V9N+IPgB4bso1+x3+sB2PBnnixjvwI6wZPgno6A7tTvQc4++h/9koA8Cor3xPglpGGaTVbkIB/fXP5bKVfgroyyoTe6nNAeS0bICB/3xQB4FRX0pa/AzwpM21r/AFpT6+dFg/j5dbtl+zl4PnJ3ajr/AAM/LPDn/wBFUAfJ1FfX8n7NHgpEZhqniE4/6eIf/jVVY/2bPCUnI1PXVU8AtPDyf+/VAHyVRX1b/wAM4+F1lKvqOuAZx/ros/8Aoqtdf2YvBhUE6n4i/wDAiH/41QB8d0V9Uaj+z14Rtxui1HXQoJDF54TjH0irlL34PeG4Z2jiu9XbBwMyx/8AxugDwKivYLr4X6XFckLcX/kYHztInX67eaki+GGgynauoaiHAyRlDn8dooA8bor2yD4Q6XckC2vdTkY9lRT+uK6jSv2fNHmjVr7UtRiJHKiSNT/6AaAPmuivrC3/AGc/CL8yajrxHqs8I/8AaVXP+GafBhGRqmvlf+u8PH/kKgD5Dor6qv8A9njwlbkCO/1589CZ4cf+iqpt8AfCo6ahreP+u0X/AMboA+YaK+nP+FA+GMEi/wBaAHUmaL/43UY+BXhEDm+1x/8AduIR/wC0qAPmeivq3S/2e/BN4reZf+I42X0nhP8A7SrVj/Zl8FOPl1XxD9DPD/8AGqAPj2ivsJv2YPCHGNU1/H/XeH/41Sj9mHwd31TxB+E8P/xqgD48or69vP2Z/B0IXZqXiAk+s8P/AMaqk/7OHhMdNR17/v8AQ/8AxqgD5PooooAK9n/ZWhWfx5qcbPIg/s5Tujh805F5bEcdhkDJ7DmvGK9s/ZNiWb4hamrgEDTQwzjqLu2IxkHnIFAH2DcabDNK7OoySTkf55pbS08iUMoAHTjuKvNy5PQ5oxQAYo2gc8Z+lKBSZ5oATGOmOfaqGsW/n2u4jLI2R64rQqC8bERUck0AczFaESkVp29qRKNpwakgh3yNxzWkkYWgBNzIoz8386kU7hkdPfvSFNxHcfzqvqV7HY23mysBnhaALZ49PpVa5CuoDgAdieK5c+KP3hG3A/vZ+Y04X5uWLxEyg+vUUAR69pVterlbsgqT2zj8a4XW7aawXK2d3cIAMNEVI/HvXd5EudzKp74NULzT3dP3dyy98gc0AeYvr9oW2z21zHheckZq7pN5BI4bTb0+YTzE52n8uhrp7zSfNJ+0vazoQBtdOtZM/hfTztzYFRnG61cjafcHNAHQWzRT5WRds/BJQcZ+lbFlJcQbArZVsAsBzisHT9IjtmXbe3MqgYHmKCy/iOorsdJspUQtJIrqMEEjGRQBrKouIC6tjK+lVoUMcXkO4Kg5BI5rRtivkAxrhewqmfmuPmHQ0ABti93lnAwc8DrV9lGwLk9OtRiMrPuxkdjU5Axg0AcjrNmZp2cNtiHTjqa5e80vPm/Z4f3hx87f/Xr0fU3MVu7Rhdwzz6V57q32ubeIrk7yDg4wc0AcxrWgAXBlv76C3iH3VUEnHoBVS1XRrZz5FlNdPj70rbRn6CpYdIvL8lrgyjJyCx5I79atLpNhYLvuL/ZzwWxQBqabqDOg3Wsca9AiHbjHrityPULfacxlSP7tcfc6rpkKqttJczg8Z4Vf1rIvtSnuMrDfLbxD/lmo/r1oA9OTV7aNgouVViOEJwajk8QTQzL5i/uSe3f8a8luLiW0Rmx5jEcsDu/PuKp2niG7gmxDO2zqUbkfiKAPoOGSG9ty8OHQj5l7isy5t2hbH3lPKn/PeuN8I+KYmnRZVMErfLuU5Rvr6V6MHivIdpxkjII9fUetAGLLGTavg/hWcsPJLcc10JgYBkcAN/P3qhIm1tuOvegBNNmNrMDtBBHzD2rqrW4iMayLlh27VzkMatxjirsSNDh0BK919aANqG+y5Dpx6r1q+pVlDIQQehFYcEgfGDnPQ1o2DKAVAIPfPegCW5UOoJOMVRliDHryDWhOMoeM1TA+cbs4oA/NSiiigAr3n9jX/kpmrf8AYGl/9HwV4NXvP7G3/JTdV/7A0v8A6PgoA+xB1paKcQAM0ANbhab6U402gAJqKWPdUtIaAI4kCdKlFCimyv5aE8ZHv0oAZdTrBGXbn0FcT4nkmnlSSV/LQL1JyevYVt6he7ifLO9z0x2rlNfvreOBhdyeZIORHG2Wz7ntQBlpPbwTnyYy8g4Jfn9KlutTEBBuriOLaPuu4VvwFeba14su7hCsIWzg5BER+b8W61g2i3V6xEaOzN/y1c4yfqaAPUB4ysYnaM3glYHGBGx/Wrtn4201mVS0+PXZmvKzplzJP+8uUVzgAgZJ7VcttI2lXkumVgccjigD08eIdEmkET36RSMflWdSg+mTwK27SNY281WUxuvBU5B/oa8Uv9Du54j/AKRbz8kqWbYT+dLY3viLRY4I4o7iEJ1KnzEx+GeOlAHvkccLyJvQZ7MtbDKY7dUjfqckHqM1wPhjxlZz2aS3zKkgXLRjOQfTGOldtoVyNUTz23KxOcDp+FAGzbJtt1CtuHqaQw4Kk8vnOasqABgDA9KMdaAE/nS96UdRQetAGTqERlQoSBngZ74rkLzyYJT8uGHG5vWur159i71UbtpOSfyrwzxt4pvJVmt7eJUk3FHmJ4XHXHqaALXjDxoLaXZazJGqnBxyW+p7fSvPJ/FMMt5HM8bXDDI3SMcCsO/sr2e6KxK875zkd6gOi6kSVa32BTuO9wOKAOuk8RQLAubOTzCCFCyfrg1mprtkSvmJcIx64ww+tY5sriNQ95LCiLkA7if5Vl3iTNiOAg7upyQSP6UAdpFq1vPKotb1d/cSHZ/9arsrkyr9ptwd38Z+U/ge9eXOzQkLLGyEdM9D71paZrV5aFfs104jPzFH+ZD+BoA9c0OJTeI1vLny/mKNwT6DNd5ourSWkwRsgDqrHj8K8p8L65bXEY+0qLW4c/fTlGH9K720nJVPOAmiK/K+e3qDQB6la3EV/b7ozllOevK1Uu7Y+aQRz61ylhfy2MqywOXTIHuPUH2ruY5I7y2SWMjaef8AdNAGbAjI21q0o8FADVd1YSMGGCOtTxDC8UATxRhHJPSrULbJVII2k4qCMg9uacpKkDnigDVYZ4NQ7AH6CpAw2KT6c0wSK7YDgH0oA/MmiiigAr3j9jf/AJKbqv8A2Bpf/R8FeD17x+xucfE3Vf8AsDy/+j4KAPsYUE00H5sYp1ACGkp1N+tABRRSjrQAjEKCT0Fc/rmpx20DS3EgigBxz1P0HetLV7yO0t90nf7q9ya8s8SXF1qdwrPJ5cMYJLn7o9gO9AFfX/FUkxeCzDRwNwCPvv8A/W+lc4Y7mc/vCYl7Aj5j+FShUtWZrVTtY8SPyxPqPSqGoanDpzh7qfypuu0Hc5/w/GgChqdpbW2Jo4d05OTv5J+grLuXldg5bbkHGWwF+maq6n4vkl3xWcIQkkrI3zEn+lcBq15d3E/mTTSSeqlun4UAd7NqsETp597AJB1BfJ/SlHiPT5WKi+jQHI5P8q8u8xVPzde9G4uvzL79KAPW4ZllWCKG4jlXdg/N2rc0K6e1u184kLG/3G5BrxnS5nV9iOcgZAbkGuj0vxLdWhWMNujzko/ODmgD6XsIrDVbcM8UTu54dRg12GlWX2ViIFBjPbpj6V4t4H8VW10kCMVicvnaeBmvbdGl85FO4EgdjQBrjpRRSigAobNPAwaa3egDC1+CeSyl8vAI5JPPHfFeX6xDZWzTyXISTf8AMFZcg5r2S7QNEwPpXjnxDtYLCKaeIF3IyIs9fYelAHneuXiCWS1t1MKAHYq8c1zU2YoS00xLvxtLYzzWdq3iK5kkZIVCN1LMPm/A1y7TSzOzvK8mOuWoA3tSlWSRSbiHKZGN33agt45NpKSIzZ6Bua5eUhTuBJ5OCTUAZvl2sw3Z70AdwoZQftAYICM8ZAoh022uJC43RAnAK8g/UVzWnXN5EPluZAB0QnOa6Sx1yEsqXluAw6SRcEe5FAGz9guLMB1Cyx9d684/CtjQvEU1p+7DCSEHmN+n/wBasaG4E7CSzmE4PJAOGH4VZk8mbiZds2OJV7fUd6APUdF1KDVSJbCQiRPvRN94ev1Fd94ZuTja3RuHUdD7ivnTTnudNuY5FkKkH93Ihr2Dwdry6gFSYql11UjgSf4GgD0m6jyCc5ZcA+4qBZNvBqzbSCeBH77dpqrImG4zwaALEUmSSelSxn5snnmqgOMHt3qeFxkY5FAGn5n7vHSqsfMgOead5gK8HjNRggNx1FAH5s0UUUAFe7/scf8AJTdU/wCwPL/6Pgrwivd/2OP+Sm6p/wBgeX/0dBQB9hZ+YDvTxUBb95/Kp6AFpKKQ0AL9KHYIpJ6UoqGcjad3QdBQBzOtBppjJMcIRkD1xXC6z0mnnmEMC9zwB/ia7zxFKsFs8svLY+VB1b2+leJeKbu91W5cOCAhKxwL/D+Hc+9AGZ4h8TOM2+lfuEPWZvvt9P7ted3dy7XDb2LzbupJJNdVdaQ/D3TFAR/qx1P+FQTwQpCAsQjAGCy/eH1oA5hrG6ZXc/uUPKlutKLKKQAuXYnjfjGPwrWkt5hGXRS8ZyvmHgfU1QaaK15uJ0QYwQnzZoApS6ZF97YnyH0+9UUlnabjmA5PGdxH41ch1CyLmMSurdiy9aie9spJAqXA5ODlTQBZsdOsEVSXdCw+XDHOavX/AIegZ45reaQ7x7Hn6VUtobVZREt0EckON4OPzrtfDNsElZ3VJUYZBUhto/CgCjpmj6jYvbyJGzqnzZA5/Kvor4fXBu7S2YbsDLkH+VcJocIeVdpyegwK9W8M20UUTsqgSnqRxn8KAN0U5RmmgVIvAoAD1Aprd6eeOlMb3oApahuMRVASSOa8/wDFGkNdo27jPGQM16S/Q1z2sAvDJ2HTAFAHyn428K22napL5tw+ZRvVR0BrGi0qwFjNMyOzqccyEV2/xWeOLUl8yWO3AJBLdT+FcVHqFh9gljRZGBJw4HWgCj/Z1ssBPkrgAkDdmmm1tEAHkqD0yADUcesW4t5NsMuVOOcdKpjXY2O1rX5ScjDc0AaElnZ8CN2jkb7rbf6VTm0y6iQsn71Dz8nX8qX+2LF3Bkd4j0G4ZqxFI8ymSCQSoDwVOfzoApQzvbOGgYpIOuOoNdLpOspcOsd+Ar9fNX/2b1qgRHIAl1Gsjkde6/jTBYbSfsrbh2Vuv50Ad7BGV2blR43PynqHrSsopLaXz7YsyKQSM8qf8K4TRdVm0+Xy5QXjP3o35/KvTvDXlX6i5tG3Rr99T1HsfagD1vwnqBurZFkI83aCT/e9a2buPkOBwevtXHaD+42SRjDKQSortA6zRBh91x1oApE4HHTNOHy8jBP8qSVCrsp7GopH560AW0k+XrkCnK/Qd+9Ukk5689aUTfvBk0AfnZRRRQAV7t+xz/yUzVP+wPL/AOjoK8Jr3T9j44+JOqn/AKg0v/o6CgD65DkzGrkbbkBrNicFzyPT61oQHK9qAJaBRQOtAC9qoX90turM+CT91fX3+lXJXEcbO3RRmuU1KR53kllOFH+cCgDC1aWTULlmLAAcFm7fSub1K1h5SFQsneQ/eP4/0roJj5ucfKq9ecAVxviLxDFbboNP2yS9DKT0+lAHO+IQlinm6hKVUfwj73/fPavPdU8UOgZbCEJzw8h3N/hWzrDG6kLySs8hPOcnNchqWnq7AwZZ242qP05oApXOqXF3IRczOWbggHg/hWeYriF8Rk4Jz61oPpF+Yt7wfZwDgOxxke1Oi00I2ZJ2LdenWgCgrsZCjRhSOrYqWWMhgwwyA9R6VuNZpcAb3lVgMDgVqaRo2mXKvHOZi5HykOACfwoAyNO2XDRzTABgdu7u3HT+VaGkXElnN51rK4fp1OOvet9/CaRmCNN2xQCd2TkmnW3htFkfynj3jgpkgk0AeheEPEAknjW7g/eEgfIf8817ZoEqSIBHk5XcT7V4j4Q8PTGNBcHGRnJ43H1/lXs/hO3ktrUJK284wSOn4UAdCKkHAxUajNSDpQAU1qXvSP0oAhlYIpZugrivFWpm0sriUEgRqWxXY3Qyh7iuJ8W2YutOnicYV+CQOTzQB8pfEK7lu9VV5iWZVLH8T1rAt5Qul5Iw+7djPGK9Q8VeG7CW72rDP5uQCTIcY9KyLnw1ZpBn7IqhAeCxH9aAPM5WcIzrjk8A1WdyBnOXIznHArvNQ0/ThZ58mNTu298iueu7aF5SsKKqdBgZJxQBz8CbmBk+WM88nnFTxXBgcG3ZkPYqeav3OmoqAkFW9ec/lUD6dJEo2ushPboaANOz11x+7vYBNHn768PXS6esNzF5trOssY+8o4YfUVwoSQNsMbqc4wa1dLV4J1ljZ0kU8bf880Ad1HaJcqFkT5cjEmOV/wAa6XRTPo86PEf3eO33WGe/vWPoWs29yqwXSrDccBXI+Vj9O1dXCmEKyxkRfxKemPUUAd5ot9HewpNbnax4Ze4/+tXaaaS1tgA4Hb0rxbTJptPvY7q1kYwg4GfT0Ir2TQb1Lizjmi+6wwV9PagC1dAkBsdcCs+RGJ7kCtWc5H6is+ViuTk+lAFYttZg55FQ+bh+adK+WYnNZl3cbGOGA4zQB8G0UUUAFe4/shkD4i6tn/oDy/8Ao+CvDq9t/ZLfy/iFqxJx/wASeUf+R4KAPrOJvm/l7VoQP93kYPrWLFL856ZrSgkzjAyaANIcjinUxCTin0ARzKHQhvunrXLawNhIbhAOceldRKePauH8YM95E6W7YIOMg/f9qAPPPF2uyTb7a1BW2GQSB941wUiTSSYgQsScc9BXd3unLGu+8DK4HEO7+dZNzE5UgMFT+6q0AclLpw2kTzFiD9yPCj8TVeSNoo8W6JGTwWXlmFbOoWUFtE0148UMajI3tgt9B1rl77xNbQqyW8Hn843udq/gByaAC4Jdv3srEg9l/WnnTTJGHxGi/wB6T5cD8aw5/E17JPuQxouc4RNtZ8t1JdzM0ru+f7xzQB1irYJkve2/mqccAkVuaBZafndBexZfG0bT8pFefozFwoAbnp6V2fhGGRkXyEbzGO1GxyPWgD0WAW8OnmF7+AsxIUkEEH+lLoHh3F3Hco0U+1syLGeGPvmln0KGO2WW8k2yY3E7uD7EetXdBtxFd74WdWOARnA/KgD0DSdKWa4CtGoiJyFI6V2ltAkMYSMYFYXhiZ5FYTgBwMBhzmujj6mgBwTFPxSjpS470AMxTWHvUhpr/SgCBhWLrUS+S+8Daa23OP8A61c3rrPIpHTtigDx/wASvZrqUxBeRQ+CEXH45rMujbS2TxeS7y+pbp3rb1C3Uao000e2PcQAf4jniub1GORLlyu4oc5OcYzQBwF7AwkfbaxleWO5jjPpWAL0WjPI1mpkBO1w/T6V6Reaa32a5EahmQEl84znngV5nfWjqZJHwx6DacgUAQJe28rkySuhz/y0Xd+oq3Hbb4jJGVZFPVecflWQYvKOMZYjnA4/OofNlRy0bOjD+IcYoA6aSMS+WJTvUdF6037CgXdA2w9dp/oapWOpPhReRh0HV1ADf/Xrctporpc2DiQDsfvD6igDPV2hf99lG6kGu08NeIm2JbagxeBuFc8lfSuf8lJQBMMnpj+vtSLZyW7h1+aLP3j/AA+xoA9i0793gja8L/kwrv8AQj9hWNAcwsMfSvH/AAHqjK4gnYvbcYY9mr1m0cKoU4Knof60AdS5zGRnJ7Gs+dsjrUlvL/o4BbJQ9u4qvdNhj0596AKM8oBOc5rn9ZuvJRzkcqe1aV/PtZiTgda5LxLcH7MxBHHFAHyBRRRQAV7H+y3KYvHupHY7htLdSV/hBmh5PtXjles/s1Er48vGUMSNOf7v/XWLk8jj8/pQB9WW0+W61sWEg8wfrzXIwTnzMZ5z0Pauk0tySpH1oA6aNtxGDTmOFJqtaNktmpp22Qs2MkDIx60AZ+qXoVDAn+scc49K5y6iEYyfmkx09KvzAqXkY/vmGSf7vtWVdXEccLtK4UDqxoAxtUtY7hGMwBx0f+7Xl3ivXhZlotMCyleDcEcA+w/rXR+LdYa6zDHuSAHIVT9/8a8/v08wMI9z99o/woA4/UriWedpbmRpZCTksxNZMixjkZz7dq6y50KWf5pNkJPQkZJ/Cqs2iwxSYG6ZwOr8f+O0Acnt3TDamSe4FW7e1uMFhEVOdoJ4z+FbptWV/wCEZ6Ljb+lWbZSnzMPlzxkYyfagCrb6PfyMP3UcmMdHGa7jwnbXkWp2kMvkxQq5yQ2Sox7VmaREj6iqvvCj+LIr0fwfpMl3d+YOittU44wfWgDWXRftk9ussr+VgkqF/HrXRaBoqW00wjVmhJxlh6e9b9np8cIQbSHX+Lk5q/aW8qysoO1M8YoAuaRaiG1UnqefrWtEvFRxp8oA6AYqwqnFAC4pwFLjpmlxQAwrmmMOKmxTSOKAKbjBNZOqwgxN5jKO4Nbci96zNWgMtqcYGAc59KAPMdRgsrjfnZlSdwJOQaz49JsZzieICMfM7AkbgOgrO1nVNO0m/kW7vEmOcNEgZsfjTbXxlozj7JD9oO4cgxc/jz70AM1a0iWzu2toY0D8buvA7V47qunw2k7RMuQ7Fsk/oK9d1rVLD7NsjZ1jJ+b5eAa8116bTricQG9yx9VxigDkrq0tMlkLK2fuhuTWe6TJjy41Yen8VbdzYtE42ypPGeQyMD+lV2gIIZugOQDwaAOfABdgY2WQdmOKtWzNA6yI5Rx3Q8itaWAyRlWiB/2WX+tVpNMEefLYb/7jHP5GgDoNJ1C1vEUXZZJ+mQBhq6S2smmUZYGL6dRXn1tbOrDzSVXsuK73w9qSoiwTnchPB6UAbkFmtkiPCuIgPuD+Gu+8M6mLiAW8rYcDKE9/auSDKRmMDZ2oJltZI5YNyrnJwfuH/CgD1XTJ8h0Y844p1w+5cnqODWNoV6t3HFOpwfuuPQ1o3T/ISO+KAMTVJss6k9K4bxVehLVyTxyT+FdRrU+2R+cYry7xxelbVgDzJ8o/GgDwaiiigAr0r4A3Edt44kaR0UtaMqhicsfMjOBjvgH8q81rrfhm7xeI2ljbDxwlhz1+ZfzoA+rrecb0wcgnr+NdVpVxmRF4Fea6DqAvIYZAcDOGHoa7jSpSZAeM/wAqAO4tpRszzyeanmfCKvfrVG0bcUXoQBUl2375vbigDJ1aRbeJ3kYKo5ya8t8S6q2ou0ULPx9xV53V3PiRm1KJ7eJsKOd3bNcNc2TWjNHFgSH78pHX6UAc2tjdxDddu4iY5EanJH49qd9pgiX5IVjYDDFR8x98mtCWORx5ZkJc88ZOQe1c9qt9bWKt50omlB4jhxkexPb9aANWz8NX2taXqWqafHG1tpy77jMmGIxk7U5JwMnJwDg4JIxXM39iEIkee3iXrh2HStHwB8Tn8MeMrW5uSsWiXDC3vo85xGx4lPU5QnPupf1rO+M3hN/BnjSSC2y2jaiDdadIDuAQkb4s/wCwSAOvysnJOaAMyefTihUB7lwMjHyAfQnk1Te7kR8W8KRqCSQctn8e1YiQSTSgxsTkjcfxrRkV1GFZMgcnPBNAF+GfUZLuNzcCGB+MqAMceten+CNQv7GJmku5pWYbAVA2j0+v1rz3wnALuRVkiLmNg59CvfH44r11Y7SKyjliVlUHLADp7UAdPp+rXZRRPNKxbBBV+lbuma9K93FA7s4Jxlv615+uqGO2AtoZN+dqhh1/Cup8BWct3cvJOuxBh2VuuaAPSo+asJyOKrRnrVqIfLmgBwHFOxxSgHFOA4oAZimsKlxTXFAFWUVQv1DWsysu4FSMGtKQcVVlXOQRkGgDwDx/4c/0tpYowN33hj0ri7ZoNPvWmnjzxsGOCvuK+j/EGjpdxMWHGCa+dPF9rNDqskUttNCik4IGfxoAoX96iRNGFLRu3GTzXHa7GZWJiC788qRg4rr7nTne2V1ZWRRtBHXPuO2ayrqFdjCRFIC/MehoA4aZG8gbMhx/dPFRQ6lPHhVYuQerDd/Ors4AmZDypbp0pLq2JcBU25GcgdfxoAtWeqK67LgFG6FkGVP1HWtWKzVoxLCUkjP9zkVygt5N/HIHAwa0bW8ntJAUPl4656H6jvQB1kMKSJtmhVx39R9KjuLZosvCWeIdj1UfSn2OrWV3Gqu3lT9Mfwn6HtU0m5X+Th+xPX8aANHQtWPy20jAseFJP6H+ldVCB5RVvmVhhh6+1eftZgHzoI2Eg5dOx9xXWaFqH2y2WJyTMi5B7t/+qgDrvCUzWd88ZfMbDg46+hrpbqYiCReNwGfxrk9MOLfHIc/MDWvJeg2cUg+8eD9R1oA5zXbksXC5X3z1ryPxxdh7sR54i6/WvTPEswhknY9F+6PwyBXkmuL5skjNyzHJzQB5zRRRQAV1fw4x/bdwSMkWzY9vnSuUrqvh3/yGLn/r2P8A6GlAHs3gy8MGomN2xHIPyb1r1vSn+dBnjNeI6AT9s56V634cuDIY1Y5bgZoA9DtX5BzzVDVboxkwocO/LH0FSxPmT2Arn9elZrg7Oj8n8KAHSsChCnbjnNYmrSQpblrt2hTsccn6DvRqOsW9hbA3LgP/AADu1cJrOpNezM7uzN2GeBQBj+KNfuizxQEwWn9xDy/uxH8ulcPd3crSB2I4PBHauuumVzkxhjnnA6isK7soA5IQoSeFZuv0oA52/wB5kO4KwOTu9c9q9r8DA/E/4UXPga9OPEmgqLzRpJGI8yJflVSeRhdxiPopQ4yM15PJYuBiGDKY+Z2bgYrpvhb5GkfELQdUu9Wm062gm/eXQj3LtIwY3yRtjYZBfnacHGASADiFuwriEJPFMuVdJFIZTnG1h2III+orStBLM23ZuGMYAwK+iv2i/Benf8I9b67pOn20E6X/AJt7LBGqmUTALvcj7x3iP8ya8Z0DSTJdxB1yGYDbnk/h/WgDqfB2iTLZRukGQTuJOASM9Oa9Gt9KnmtCZwqAjgKwY4qXT7FIrdFO9EUDG0DB9sUl1qUgmVVnjjR+NvcD+lAENslk1xHHuaR146/nXovhXT4ra1MqR4eQ8knJIFcboWkQSXyTTTMYmO790M5/H05r0qzEaxxrECqAcDpQBbjTnpVhVwKSNfyqSgAooooAKCM0UUARSCqkq4FXmHFVpQKAM67XMRHavO/G2gR6hEJreP8A0iPnGPvD0r0iZsA4XP1rF1FCQcRcnptNAHz5BdfZdT8uUOFYksgPBHr9RV3Ube2uNxiUMrKcFlHPrXQ+NNHjhnl1FLWY8ZkRSMj1I/KuMa/tRCrhzGzg7A/AFAHI6totpHKWjTgnOegyKytVtFa3Bhf98CQwPcetburO90JIchmByuw59+KxL2cQwohiUkDlzwaAOWuzNASJUKJ0yOc1X+07RgvvVuzelbc7ybSGG9Dx04FUX0+F1zHuTPIOOKAKqPnknAB4ArpdE1UIogvmd4sfIw5ZP8RXO+R5YRdxA65Pf6VNE20naeeuQelAHoeCFRoeB1Uq2QffNWrRCZUuYWKlOXUcfiK5TQNQaMiNxvtz97/Z9xXao6LDHJbkGPH3uuaAOpgvEljimi+63VfQ1oBwbVx1AbcK5LS7hYZxGW/cTcHJ+63aty1nZre5jJw4HT6UAc74ufLgA53Dk+pFed6quSemK73xAcoh9CRiuH1Jc7uKAPLaKKKACup+HmRrFzj/AJ9m/wDQ0rlq6r4d/wDIZuP+vZv/AENKAPVNBH79q9P8Jt/paHnCqWNeY6H98/XNeneERueQk/w4zQB2sU+2ykkJwSOK57XbtYbB33fvf4B6n0rSvbhIbMlzhFGT+Ary7Wdae7uWYsVAJCr/AHVoA5jW9WluJpHnLkk4AI+77VmxXUhK4bzcnhBnP4etaupWD3SNPbfLGT85b+L3HvVS2igt23RAkjhnY8k0AaNrZTXKN57CMn/lmp+b/wCtVmXSUjVtiEFh1ZeSazornEp2cerkVpPfxgBrmYW5wArMeD7YFACJpqWyn7RGrh1wwxkEVFLpBYl432ID8oYDGKmGqSAiOxikLE43lc/kOlaGneHNU1i7Vp5+WOQrDJxn9KANLwv4o8rw7eeCfEk2/Rb2ExWV22SLKTrGpIGTEHAxwSvT7v3bPw+8ParcXSXEtj9lCrj94MuT7dgK9C8I+DNPtNks9sJbhf8Alswzj6V3MNnFFwigADFAHMx6G2xwyOx2YJz1qLS/Blot2Lq5RpJAMDceB9Aa7QDjApVGeKAK1papBAIkjVUHAUDoPStCCPoaVEwMY49asxrxQBIowKWiigAooooAKKKKAA9KrTdas1A4yTQBSlXH0qrNHu4xWhIp5Haq7DBoA5jXrFWhYEhgw6enavGPE2hJYXBbyAbF2G5f7h9R7V79fwGRSSO2BXmXjSwmWAquQucEdsE0AeEeMSukXcNxZhVt3+XcB831x71iC+EkZZow3qB3/wAK6rxfb+S8sE4WR9xVHbuP8a4e5i4DqM7TyB1oAuW7wyEhV2q/97kU0W7xHds3KeRjuKy4rkRcgnk9CKtRSzB9xfnPTqD+FAFmSAMhyp2k/MF5IqE6UkpzE4BH3lJ61qRMkqxmP5XIAKHv9DUpRRI38J9QKAMiJ/LYAA5XgAjBrodE1QQjypDiFz1P8JrLurdZwSflkHAf/GsyWcwBoWyH7+1AHeXM/lsUYjy3HPt7/wBa6vRpGmtDMeZGHlt6Ejv+I5rzHQr77TB9klOXXlCep9q9E8N5/s94WHzqAcfjQBl+JFCttBOM5HtXGX+cN6Gu58SJuMbdgCuK4vUF60AeSUUUUAFdR8PSRrFwR/z7N/6EtcvXT+ADjV7j/r2P/oS0Aer6KcMORXqPhL93aySHq7YX6CvLtI6jHWvVdECwmOE9IkBY+/U0AQeOr82+mBQeEZXfnqPSvMI2F3L9oJIQnhf73/1q7XxK4vpLmJuVbgg9z2H8q4G5m8n94pO4nBA6fSgDpEbzLb72QDgBecVmX1lvLyRALt5PofWs59Ujhtywckn5toODmsq61aWVwxchfQHGP8aAEvNWaNmitsIFOC7/AHj9B2rNS5lnuCChlb37/jVwoNRB3xpIez4xitSx0+GDa0J3sDg5PegDc8L28kcUbzPtx92NfvZ+te6+DtOjgs45ZE3TNy/c5rybwRpMtzqyF33InzAKOnoK9t0g5AjhGVXjAHf3oA6W1UpF2B9BU2e1V4Fcgb+foelWo1GABmgB8a57VIiZPSliXAFWEGKAFROKkAxQM45paACiiigAooooAKKKKACmMKfSHpQBXkGTULKCasMahfA+tAFYrya5rX9NM6uowxbkdq6hsbuKrXMIlQjv1oA+ePij4ZkksmeOMGWJtwOf0/8Ar145KgkyrKVAOCSMEGvrzxTZROWR2VgV9OntXz5440m1sNQLRxkrKTuB4570AeY3lu1vcnJIVuR6GpkKDY+0LnqBW3ewJc22YkUyR9A3UVzdzPJEgWfCtnHFAE1zLJbKu2TMTc89qtwatHIoS5Y9MZB5X/GspL1mXy5MHsPSqc5CSE4AxyOetAHUOxkj+RgUPdT1qpdRpLEq7cBR8rdwfesix1IwNgtujJ+ZT/nrW6NlxGr275QjOe30+tAFLTBJFfByNpiP5mvWvDlyssqTKPlkTa3PevNTGEUFPvL90DuK6nwPd4byifvNlPrQBv6+hMcyd0YVxF+Dk5ru9bG+OVyeduD71w2onsOlAHkFFFFABXS+AzjVrj/r3P8A6Etc1XR+Bf8AkLzf9cD/AOhLQB7D4bXzbyCPHBYE/SvSNMc7rl88kdfQV5z4TI+1hj/CpNdzvMGmO4xlyPyzQBkalIpeRui7iRXAeJblLSQyfKWf5lT09zXVa9qCWisxOSfuL6n/AArzTXGkvC5Z9zMd3XvQBj3+qyM5deWPG4fxU+yv1fLSOF2+3X2FZEiMZNh+VgeRmh2BzzsCDmgDsLS8klZEi6HgAd66rRbMzsIFQhs7skcVe8EfA3xhrOm6fqdre6JBYXUaTRzvctI3lsAchUTGQD0LDkEZHWuu1fwpZ+BmW11HxONR1hwD/Z9ja4cZH3pHZ22L9Rk9geaANrwvatZxRiPjnDbeS31Neq6VGI7SMAAsegHf1rzrwejSRp55UKQM9gK7uLVrdX8uBgQOP973oA6KNQi471OhwfSsu0u/N6kHPHWtFOWFAFpGweBUgYk9ag6YqdRwKAJVyetSAYpqDjmnUAFFFFABRRRQAUUUUAFBoooAjcCoJRVh6hfmgCq4OeKibpx1qeQcZFQnrQBx/iZ+ZAU3ccY614143WDVLd1Rz9oU7tuOuOuP89q9v8RwDLE9fSvGPHenkrvh4kDZDdCDQB5LeLNbXY4K7Thlz0/+tVO6so7oOWXbLyVb/Gmy3zpPNHd/MSxBJ6j3psy4i3wSFkbj3oA527R4GKyAqc8H/Cqkk25fmzuHtXTXNkbu1DOu1RwCOe1Yc1mtqxBYEevXFAFTyiQPM4B5Famn3zWpCv8A6o9QP5/WsyVgAFDc9jUT3BA5/E+tAHYtIOGRgVbkNWppEhi1GCWP/V5LfRq4fRtRPmeS2AjnAz2Ndroh3O24cY2/Q0Ad/qMgkgl2c7494/LNcPqBzk8V1dvLu06B3I3KCjCuU1Fdjuh4KkigDyKiiigArovA3/IXl/64n/0Ja52ug8FHGqy/9cT/AOhLQB7J4RJa72dcr/UV22rSKmlSOSFVE4+grhfBR/0qWTsqY/HNdB42ujBpQtsjdNH09B3oA821DU2vbmV5CQBxGp7L2FZsymVcA5btis+7lkEgZckr196et0SN2AD7Hn6UAd94Q+Cmv+KNOi1y9u9P0LQGUS/bbuUMzx8/vFRTgAf7bLXRwX/wg+HhX+yLC48b67Dyt3OR9lWTjOCR5eMjIKI5GfvV5iGvNUtLSwuZ7y5ggLfZrJpGaKHcSSVToCSSc123hz4em6dbjUSCeohH3T9aAOqT46+M9c0yXT9J0iztNTkuDtvbZSyQQYGFVXyGkzuy5+UDHyk9K3hLwHcNdG71u7lluJXMkpZi0kjHqzu3JJ9TXa+H9Hi06FI4IVjI4HGMV1VpYHzCME47+tAFfTNGjWIIsf7pfU810em6NCoVvJUY6EjqKt2NntRQ9aqqFAA6CgBkNtFEuERVx6LVlE70IvPNTovAGKAE29KmSnKlPCgUAKKKKKACiiigAooooAKKKKACiiigBklQsetWSMioH6GgCtJ0qA1ZkXrVdh8xwaAMDW3BkdXIAxwa8z8WWaSSLlScsee3evRtby5kLqUOeMjgivP/ABLKTEVVXbByMDg+1AHz14s0l7a5afaxGTvHp71zyz/Z2DIC0f8AEK9P8QRxvkyKcEEkEYyK838R2P2Pbc2chMLDa645Q/1FAFpbmO5hbbJtccgHgGqc9xHMMXCBWJ5IHUViNeeXLujztI+ZT60j3XnOM/exkH1oAi1OAxMzIcxnkewrNMjED0+lafLjI5zwynvVCaLy2yudv8qAEjIByOD2I7V6F4ZuzNZL5hzKMK2RyPQ1wFqhdg3GB+tdPolwYLlWbO1vlagD0q2LNYHnuMisDWsrdPnvg1u2DbreWM4ztBrB135Zxz/ABQB5HRRRQAVueEXCam+SATEQPf5hWHWv4ZYLfvkgZjPX6igD2nwZ/wAe6Y+9LIf8Kt+OXaW6LBvljUIPoDVPwexW0se3U4/GjXJGuGlKDO5j/OgDzjUYxFdPznPNWPDuiz6ncjykAjzw7Dj6+9ay6FLqd0iIpBQ5bj+HvXqXhnREtIYo44tqjpj+dAE3hDwvFZRIEjUufvSHq3+H0r0Wx09I4wqj8+9UbGLyVVAOeK6SxhxtB+tAC2tmHcYHC9OK2rG3O4bhg0+xg+QYHWtONAgwKAFRcDipkXPamquasIooAVE71OgpoFSpQA6iiigAooooAKKKKACiiigAooooAKKKKACmlQadRQBA6AmoXQA9qnkOM1RkfLdaAEkVehAI9xmsnUNKtJ/mKKrHsBjNaMkmxdx5ArMurveCEYE+1AHIa14RtZFfam4HPbNeY+Jfh5byw3CRRICwJGDtINe0zSyq+cnkZ+tZ11Gs5IkUHPGcUAfIOv8AgTULKeV4ELKnJHU1yN5YyW7jzt0R64dcV9ceIdKSOcgrlT0wK4HxB4dtriMloInVsggigDwWL5gCTlh7dRU32fzwM8DFdle+C4Gk3WUhhwSCp5DH2rPu9BubRWEiblHde1AHNGAwNtPA7VZt5cA5IPrmprxMxblwT6VnxcsCv3fegD07wrdm4sTK3X7px7VneI223eD2Wl8Dt/otzH6r5g/kai8UN/pKH+9GKAPLqKKKACtPw823UO+Npzx9PyrMq/ozFb0YJGVI+tAHs3haULY2Z7qT/OpZ1ZdRniycGQlcVkeFZd1m69TG24fQ109xb+dqMLjrIoPHt1oA2/DtgsSq23535JxzXXWkQtVDYGeg5qhosIKKe3vW5FF5rjphTwaANCxTPU8nrXS2KYK56dMVjafEOM9a6SzQ5AA4oA1bYfIMVYUVFCuFqdOooAlUVOo4qJamUcUAPUc1KKYo9afQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAQzDggVSdTk1oSCqzigChPHvUise6sDuLpkV0DrURHJoA53aWXy5eHHRsdage3w3I+tb1xaqwJHPtVfyh0P3e3tQBz2raYLm1AZcnB//XXDajpbAsGGQOvHavXpIAY8Ef8A1q5jVrELKWUAg0AeR6tosbpvVAvPIFZF/YJDatvAk3ryCegr0++sVMZG0YIxzXAa1C0LMhGeT17UAeR6/pX2e9ZYhkPyv+H1rl2h8qYx8jnjPvXrmp6ct/aMFx58fzKT39jXn2pWLC6SUr9w7WGPyoA3fCShLhlBGPKYHH4VS8VSDdEw6cirvh392J5OMiNsfyrH8RH91H64J6+9AHAUUUUAFWtOcJcgn0qrT422uDQB6h4RuAlygONrDYf6V6ZpMYnhTJy0P9a8a8NXGQhDcg17R4TlEsTOOjgf/XoA6nTwIoQmck8V0VhH8o4rm0yt1GmThFzx711NhyFwQPagDZs484NdBZJ90+lY9kOMD9a6C0G1PrQBZWpFqMVInWgCZByKnXtUKHFTL2oAmHQUtIvSloAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAEYZFV3WrNNZcmgCi4qJvSrzKMVXdKAK5GaYUUnpUrqQaTHFAEbINuKxL+A8h+R2NbzdKzb7B/CgDkry2xux0rhPE9mAzOB82cmvTNQXKnjB61yGsQeZuGKAPLpYzFcDHfg+9YXiPTFMErxrz6e/rXdalZgMzhfpWPeRCRCG6FcGgDhdOGy1uCBxtA/Ouf8TOAwA6qgH9a6q3hMVkysOXkb8gcVxHiOUPJK46E8fSgDkqKKKAClpKKAOg8OXOx9pPINex+CdQUwyIW5QqfwJr5+V2Q5Rip9jirUOpX0GfIvbmPIwdkrDP5GgD61iulknyCMjArqNOuVYDB4r4rXxFrS/d1jUR9Ll/8alTxX4ij+5r2rL9LyQf1oA+9NOnVuSc10FtOpA5r88F8Z+KE+54k1pfpfyj/wBmqQeOvFw6eKdeH01Cb/4qgD9F1YN0qRTyK/OceP8Axiv3fFniAfTUpv8A4qnf8LC8Z/8AQ3eIv/BnN/8AFUAfo2jiplfivze/4WF40/6G/wARf+DOb/4ql/4WH40/6G/xF/4M5/8A4qgD9JlepAwNfmr/AMLE8bf9Dh4j/wDBnP8A/FUv/CxfG3/Q4+JP/BpP/wDFUAfpVRX5q/8ACxvG/wD0OPiT/wAGk/8A8VS/8LG8b/8AQ5eJP/BpP/8AFUAfpTRX5rf8LH8cf9Dl4k/8Gk//AMVR/wALH8cf9Dl4k/8ABpP/APFUAfpTRX5rf8LH8cf9Dl4k/wDBpP8A/FUf8LH8cf8AQ5eJP/BpP/8AFUAfpTRX5rf8LH8cf9Dl4k/8Gk//AMVR/wALH8cf9Dl4k/8ABpP/APFUAfpTRX5rf8LH8cf9Dl4k/wDBpP8A/FUf8LH8cf8AQ5eJP/BpP/8AFUAfpTRX5rf8LH8cf9Dl4k/8Gk//AMVR/wALH8cf9Dl4k/8ABpP/APFUAfpTRX5rf8LH8cf9Dl4k/wDBpP8A/FUf8LH8cf8AQ5eJP/BpP/8AFUAfpSaYxr82f+FjeN/+hy8Sf+DSf/4qk/4WL42/6HHxJ/4NJ/8A4qgD9IyaiY5r84P+Fi+Nv+hw8R/+DOf/AOKo/wCFieNf+hw8R/8Agzn/APiqAP0aYgVGx546V+dH/CwvGn/Q3+Iv/BnN/wDFUf8ACwvGn/Q3eIv/AAZzf/FUAfonIwUZJrIvZfmJPSvgI/EDxkevi3xCf+4lN/8AFVGfHXi5vveKdeP11Cb/AOKoA+6buYDPTpXN6lKuTzgHivjdvGviphhvE2tn638v/wAVUbeLfEj/AH/EGrt9b2Q/+zUAfUOrbVDYxwPpXMzMHRlXqWr5/fxLrsn39a1NvrdyH+tRf29q/wD0Fb//AMCH/wAaAPW/EUyQ+fs4A+Vfxry/XZs5GazptTv5v9dfXUmf70rH+tVnkdzl3Zj7nNADKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This plain frontal chest radiograph from a 56-year-old male demonstrates a mass abutting the right cardiophrenic angle, a typical appearance and location for a benign pericardial cyst.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_34_32303=[""].join("\n");
var outline_f31_34_32303=null;
